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Abstract 
The work below describes a new assay called strand-specific primer extension-
quantitative polymerase chain reaction (SSPE-qPCR) used to study the repair of 
DNA-protein crosslinks in mammalian cells. DNA-protein crosslinks (DPCs) are 
bulky lesions which disrupt important cell processes such as transcription and 
replication. They are formed by endogenous molecules such as formaldehyde 
and exogenous damaging agents such as ionizing radiation. However, the repair 
mechanisms associated with their repair are still unclear. Chapter 1 of this 
document provides background information on the formation, biological 
consequences, current models, and methods used to study DPC repair. Chapter 
2 describes the SSPE-qPCR assay and its uses/limitations for studying the repair 
of plasmids containing DPCs or other polymerase-blocking adducts transfected 
into mammalian cells. Chapter 3 describes results generated using this assay to 
assess the role of nucleotide excision repair in DPC repair and highlights the 
versatility of the SSPE-qPCR assay. Chapter 4 extends observations made in 
Chapter 3 by using SSPE-qPCR to examine repair of DPC-containing plasmids 
in the presence of a homologous donor. It also provides evidence for 
homologous recombinational repair of DPCs in mammalian mitochondria. 
Overall, this work provides additional insight into the mechanisms of DPC repair 
in the nucleus and mitochondria using a quantitative, flexible assay that has not 
been available previously.  
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I. DNA-PROTEIN CROSSLINK FORMATION 
DNA-protein crosslinks (DPCs) are formed when cellular proteins become 
covalently linked to DNA1,2. Studies using mass spectrometry have identified 
hundreds of proteins that are capable of being crosslinked to DNA3-5. With 
numerous potential crosslinking sites per protein, it is not surprising that 
thousands of DPC variations are produced on DNA. DPCs are commonly 
characterized by two classes: enzymatic and nonenzymatic6 (Figure 1.1).  
Enzymatic DPCs are reaction intermediates formed when an enzyme is 
covalently linked to DNA. Normally, these enzymes reversibly bind to DNA. 
However, upon exposure to a crosslinking agent, the enzyme becomes trapped 
to the DNA7-9. Examples of such enzymes include DNA topoisomerases which 
transiently interact with DNA to relieve torsion stress but can become trapped 
onto DNA by inhibitors such as camptothecin10,11. DPCs can also be formed 
during base excision repair12. Glycosylases remove damaged bases and form a 
Schiff base intermediate in which the repair protein is linked to the abasic site13. 
Oxidation of these sites by reactive oxygen species or free radicals results in a 
covalent bond between the protein and DNA backbone14. DNA polymerases can 
also be crosslinked to abasic sites via oxidation15. Other repair enzymes, such as 
methyltransferases, which remove alkyl groups from DNA, form DPCs upon 
exposure to carcinogens like 1,2,3,4-diepoxybutane16-21 
Nonenzymatic DPCs are more common than enzymatic DPCs and can 
involve any protein in the vicinity of DNA. These proteins are crosslinked upon 
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exposure to exogenous agents such as ionizing radiation, UV light, cigarette 
smoke, and chemotherapeutics1,22,23. Endogenously produced metabolites such 
as reactive aldehydes can also form DPCs. Reactive aldehydes are produced 
during the oxidation of ethanol to acetaldehyde, metabolism of amino acids, and 
histone demethylation at chromatin24,25. These aldehydes possess electrophilic 
carbons which can react with the primary amine of a DNA base, and following 
dehydration, form a Schiff base. This intermediate can then form a stable amide 
bond with the arginine or lysine of a nearby protein to create a DNA-protein 
crosslink. Reactive oxygen and nitrogen species produced during cellular 
respiration can also react with DNA bases to create electrophilic lesions which 
subsequently induce DPCs26.  
Due to their bulky nature and ability to distort the DNA helix, DPCs block the 
progression of replication and transcription machinery27,28. They also interfere 
with the ability of chromatin remodeling factors to access DNA and have been 
associated with the formation of double-strand breaks29,30. DPCs of various sizes 
have been shown to be mutagenic in human cells, resulting in genome instability 
and cellular toxicity31. Despite the frequent occurrence of these lesions, the exact 
mechanism(s) involved in DPC repair are still not fully understood. Multiple 






II. DPC REPAIR DETECTION METHODS 
a. Hypersensitivity of repair mutants 
DNA-protein crosslinks were first noted in Escherichia coli following exposure to 
ultraviolet light and linked to cellular toxicity by Smith et al. in 196232. To gain 
insight into the repair pathways involved in DPC repair, researchers assessed 
the sensitivity of bacteria repair mutants to DPC-forming agents. Results from 
these experiments implicated a role for the nucleotide excision repair (NER) 
pathway and homologous recombination (HR) pathway33,34 in DPC repair. 
The nucleotide excision repair pathway (NER) is the primary pathway for 
the removal of bulky DNA lesions, such as pyrimidine dimers formed by UV 
light35. Its basic steps consist of damage recognition, dual incisions by 
endonucleases, resynthesis of the excised DNA, and ligation36. Eukaryotic NER 
is divided into two sub pathways: global genomic NER (GG-NER) and 
transcription-coupled NER (TC-NER) which differ in damage recognition37 
(Figure 1.2). Global genomic NER employs the DNA-damage binding (DDB) 
protein and XPC-Rad23B complex to scan the genome to recognize helix 
distortions38,39. On the other hand, transcription-coupled NER is initiated by the 
stalling of RNA polymerase at a DNA lesion and recruits XPG and CSB to the 
site of damage40. Individuals with Cockayne Syndrome (CS) possess mutations 
in TC-NER and are hypersensitive to UV irradiation while patients with the 
autosomal recessive syndrome xeroderma pigmentosum (XP) suffer from 
extreme sun sensitivity and an increased likelihood of developing cancer41,42. 
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Following recognition, these pathways converge, using the same helicases (XPB 
and XPD) and transcription factor (TFIIH) to unwind the DNA, followed by the 
endonucleases XPG and XPF/ERCC1 to make excisions on either side of the 
damage43,44. Finally, DNA polymerase delta and epsilon fill in the gap, which is 
an average of 30 nucleotides, and is sealed by DNA ligase45,46.  
Homologous recombination is known to repair double-strand breaks47. In 
mammals, HR occurs in the S and G2 phases of the cell cycle when 
homologous, sister chromatids are available and consists of two primary models: 
double Holliday junction and synthesis-dependent strand annealing48,49 (Figure 
1.3). In both models, a double-strand break occurs, and the MRN complex 
(Mre11, Rad50, and Nbs1) binds to either side of the break which subsequently 
recruits the ataxia telangiectasia mutated (ATM) kinase. Next, the DNA ends are 
resected to form 3’ overhangs by the MRN complex and CtIP and is then coated 
by the RPA protein50. Next, BRCA2 (part of the BRCA1-PALB3-BRCA2 complex) 
recruits RAD51 to replace RPA and begins the search for homology51,52. Once 
found, the 3’ overhang invades the recipient DNA, forming a displacement loop 
(D-loop), and is extended by DNA polymerase, creating a Holliday junction53. In 
the double Holliday junction pathway, the 3’ overhang on the other side of the 
double-strand break also forms a D-loop54,55. Both loops are then cut by nicking 
endonucleases and sealed by DNA ligase, resulting in either crossover or non-
crossover products56. In synthesis-dependent strand annealing, the invading 3’ 
overhang is extended along the homologous donor and anneals to the other 3’ 
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overhang of the damaged strand57. Following annealing, any small flaps of DNA 
are removed, and the repaired DNA is sealed with ligase, resulting in non-
crossover products58,59.  
Formaldehyde is a DPC-inducing agent commonly used in hypersensitivity 
assays of repair mutants. Bacterial mutants deficient in the NER and HR 
pathways have been shown to be hypersensitive to formaldehyde33,34. 
Saccharomyces cerevisiae mutants deficient in the NER pathway were also 
shown to be sensitive to formaldehyde by Chanet et al. in 197660,61. Interestingly, 
studies performed by McCullough et al. demonstrated that the contribution of HR 
and NER can differ depending on the dose and duration of drug exposure. Low-
dose, chronic exposure of formaldehyde in Saccharomyces cerevisiae showed 
the greatest sensitivity in clones mutated in the HR pathway while high-dose, 
acute treatment was more toxic to NER-deficient mutants62. Hypersensitivity 
assays in DNA repair mutants were also used to assess DPC repair in 
mammalian cells. Studies performed in Chinese hamster ovary cells showed that 
clones deficient in the NER gene XPF were the most sensitive to formaldehyde 
treatment and accumulated double-strand breaks63. Additionally, Xeroderma 
pigmentosum patients, who possess mutations in the NER pathway, are known 
to be hypersensitive to formaldehyde and UV light63,64.  
A limitation to these hypersensitivity experiments is that agents that create 
DPCs, like formaldehyde, invariably produce other types of DNA damage such 
as DNA-DNA crosslinks and strand breaks which could contribute to enhanced 
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sensitivity65. Therefore, other methods have been established to distinguish 
between ‘protein-bound’ DNA and ‘free DNA’ to examine DPC repair 
mechanisms.  
 
b. Quantification of protein-linked DNA on chromosomal DNA 
Zhitkovich et al. developed a modified radioactive assay from Liu et al. to recover 
DNA-protein complexes from intact cells following the exposure to chromate, 
cisplatin, and formaldehyde66,67. Following drug treatment, cells are lysed with 
SDS, which will bind to protein (but not DNA). Upon the addition of potassium 
chloride, potassium displaces the sodium and forms an insoluble KSDS 
precipitate which can be recovered by centrifugation. Thus, the amount of DNA in 
the pellet is a direct quantification of ‘protein-linked’ DNA and can be measured 
by radioactivity or fluorescence. Results from Zhitkovich et al. detected a five-fold 
increase in DPCs following exposure to cisplatin, ten-fold increase to 
formaldehyde, and significant accumulation of DPCs in white blood cells 
following animal exposure to chromate. Thus, demonstrating the use for this K-
SDS assay to detect accumulation of DPCs following drug treatment. 
Another strategy used to isolate ‘protein-linked’ DNA is to run the cellular 
lysate through a nitrocellulose filter to bind ‘protein-linked DNA’ and allow ‘free 
DNA’ to run through. The ‘protein-linked DNA’ retained on the filter can then be 
quantified using fluorescence or radioactivity. Oleinick et al. used this technique 
to analyze DPCs formed in hamster cells following exposure to ionizing 
	
8	
radiation68. Results from these experiments showed an enrichment of DPCs on 
actively transcribing DNA, suggesting that DPCs may form preferentially in 
regions of the genome where chromatin is unwound.  
Comet assays can also be used to estimate DPC formation in cells. In this 
assay, cells are embedded in a thin agarose gel on a microscope slide, lysed, 
and subjected to electrophoresis. This allows broken DNA to migrate away from 
the nucleus, forming a comet “tail”. The DNA is then stained with a fluorescent 
dye to visualize the tail length. The extent of DNA damage is directly proportional 
to the length of the tail69. Comet tails made due to DPC formation can also be 
reversed by pretreating samples with proteinase K. Studies performed by Merk 
and Speit, showed a connection between formaldehyde-induced DPC formation 
and removal with cytotoxicity, but this association maybe fluctuate for different 
types of crosslinks69. Conversely, comet assay studies did not show a difference 
between wild-type, NER-deficient, and HR-deficient cells in the removal of 
protein-bound DNA induced by formaldehyde70. Ide et al. used fluorescein 
isothiocyanate (FITC) to label protein-linked DNA and measured fluorescence 
following cell treatment with formaldehyde. Results from these experiments also 
showed no difference in DPC repair dynamics between wild-type and mammalian 
cells deficient in the NER gene XPA71. 
Maizels et al. developed a rapid approach to DNA adduct recovery 
(RADAR) assay to quantify protein-linked DNA by immunodetection72,73. This 
assay used chaotropic salts and detergents to separate ‘protein-linked’ DNA from 
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‘free-DNA’ and preserved epitopes needed for antibody recognition of the desired 
protein. Studies using this method recovered Topoisomerase I (Top1)-DNA 
adducts trapped by the chemotherapeutic camptothecin from as little as 60ng of 
DNA, highlighting its use for analyzing small numbers of cells. 
Significant insight has been gained into DPC induction and removal 
following exposure to crosslinking agents using methods, such as those above, 
to separate ‘free-DNA’ from ‘protein-bound’ DNA. However, most of these assays 
do not provide details on the type of protein or nature of the chemical crosslink 
that is trapped onto DNA. Therefore, mass spectrometry has been used to 
quantify the formation and removal of specific types of DPCs, as well as to 
identify proteins that are crosslinked to DNA by various drug treatments. 
 
c. Mass Spectrometry 
Mass spectrometry-based proteomics has been used to conduct analysis of 
DPCs formed by crosslinking agents such as formaldehyde, diepoxybutane, 
nitrogen mustards, cisplatin, ionizing radiation, and reactive oxygen 
species4,5,8,17,18,58,74,75. Following drug treatment, chromosomal DNA is purified 
and proteins are released from the backbone by heating and resolved on a SDS-
PAGE gel. Proteins are then excised and extracted from the gel using tryptic 
digestion or filters. Finally, proteins are digested to peptides using trypsin and 
identified using MS/MS fragmentation and proteomic software. Tretyakova et al. 
identified proteins crosslinked by the carcinogen 1,2,3,4-diepoxybutane (DEB) 
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and identified 152 proteins crosslinked to DNA. The largest percentage of 
proteins crosslinked to DNA had known DNA/RNA binding activity, followed by 
cell motility proteins, proteins involved in cellular homeostasis, and mRNA 
processing proteins.  
To quantify DPCs using mass spectrometry, cell culture media can be 
depleted of native amino acids and replaced with isotopically labelled arginine 
and lysine. These ‘heavy cells’ are then treated with a crosslinking agent in 
parallel with normal, ‘light cells’ and combined after treatment76. High 
performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 
is then used to quantify the peptides. Tandem mass tags reacted with lysine and 
arginine residues on the ends of tryptic peptides have also been used to quantify 
chromosomal DPCs. In these experiments, control and experimental samples are 
labelled with unique isotope tags and can be distinguished on higher-
performance liquid chromatography/electrospray ionization tandem mass 
spectrometry (HPLC-ESI-MS/MS)77,78. Recently, these studies have been used 
to assess the formation of DPCs in cardiomyocytes following 
ischemia/reperfusion injury79. 
To provide absolute quantification of DPCs on chromosomal DNA, 
isotope-dilution tandem mass spectrometry assays have been used to compare 
DPC accumulation in cultured cells or blood80,81. In these studies, amino acid-
nucleoside or nucleobase standards are synthesized and isotopically labeled. 
Known amount of these standards are then spiked into each sample to be 
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quantified by HPLC-ESI-MS/MS. Tretyakova et al. quantified the formation and 
removal of DPC-containing DNA from cells treated with nornitrogen mustard82 
and showed higher adduct accumulation in NER-deficient cells compared to wild-
type.  
Although valuable information has been generated using mass 
spectrometry analysis of DPCs83, these assays can be expensive and time 
consuming. Therefore, researchers have also utilized plasmid-based approaches 
to gain insight into DPC repair84. This method is useful in examining the repair of 
defined lesions at a specific site following transfection into cells proficient and 
deficient in DNA repair pathways.  
 
d. Plasmid-based assays 
To analyze the repair of DPC-containing plasmids, proteins can be enzymatically 
trapped or synthetically crosslinked to plasmid DNA and then incubated with 
extracts or transfected into cells85,86. Baker et al. enzymatically trapped the repair 
protein methyltransferase onto plasmid DNA and used a host cell reactivation 
assay to quantify its repair87. In this assay, the DPC blocks the transcription of a 
reporter gene, luciferase, which luminesces in the presence of a substrate. 
Changes in luminescence can then be quantified on a plate reader, and repair of 
the DPC is correlated with an increase in luminescence. Results from these 
experiments indicated a role for the NER pathway in DPC repair. Advantages to 
using host cell reactivation assays are that they can quantitate repair of specific 
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types of DPCs. However, since this assay relies on gene transcription, it is 
incapable of detecting repair events earlier than 24 hours post-transfection. 
Additionally, it is incapable of distinguishing from repair of a DPC and 
polymerase bypass of a lesion. Therefore, residual proteins or peptides that are 
still present on DNA, but have been bypassed by the transcription machinery, 
would be quantified as a repaired adduct. 
 To gain further insight into the bypass of specific lesions on DNA, 
synthetic adducts can be created on DNA duplexes and incubated with different 
polymerases to study the efficiency with which the polymerase can extend a 
complementary primer88. This strategy is useful because it allows one to 
manipulate the type of crosslink and polymerase to gain insight into its biological 
effects in vivo84. For example, it can be used to better understand which DNA 
adducts completely block replication and which lesions are able to be 
bypassed19,20.  Bypassed lesions can be especially important if they are 
associated with error-prone DNA synthesis and the development of mutations in 
vivo86,89. 
 
e. Strand-specific primer extension-quantitative polymerase chain 
reaction (SSPE-qPCR) 
The work herein describes a new plasmid-based assay to quantify the repair of 
DPC-containing plasmids using qPCR90. This method creates site-specific DPCs 
on plasmids by either enzymatic trapping or synthetic crosslinking of proteins to 
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DNA. DPC-containing plasmids are then transfected into repair proficient and 
deficient mammalian cells and repair quantified after various time points. This 
assay is fast, low cost, and can quantify repair events as early as 2 hours post-
transfection. Using this method, new insight has been generated into the 
mechanisms of DPC repair and previous inconsistencies clarified regarding the 
role of the nucleotide excision repair (NER) pathway and homologous 
recombination (HR)91 in DPC repair (see Chapter 3).  
 
III. PROTEOLYSIS IN DPC REPAIR 
It has been shown that larger DPCs are unable to be excised by the NER 
pathway unless proteolyzed to a smaller DNA-peptide crosslink. Studies 
performed in bacteria indicated that NER was incapable of excising lesions larger 
than 14 kDa and that these bulkier proteins were instead repaired by 
homologous recombination61,92. Similarly, Baker and Chesner both reported 
increased repair of DPC-containing plasmids by the NER pathway following 
degradation of a ~40 kDa DPC with trypsin to a smaller DNA-peptide 
crosslink87,91. Since hundreds of proteins of various sizes can be crosslinked to 
DNA, it is logical to suggest that proteolysis of larger DPC lesions plays an 
important role in DPC repair.  
In 2014, Jentsch et al. identified a yeast (S. cerevisiae) metalloprotease 
called Wss1 (weak suppressor of 3mt3) to act specifically on the protein 
component of DPCs93. This group used a synthetic interaction screen with cells 
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lacking Wss1 and Tdp1 (tyrosly-DNA phosphodiesterase 1), an enzyme which 
catalyzes the removal of topoisomerase 1-DNA trapped complexes. Cells 
deficient in both Wss1 and Tdp1 grew slowly and were hypersensitive to 
camptothecin. Wss1 was also shown to cleave topoisomerase 1 in vitro and was 
capable of auto-cleavage when incubated by itself. However, the protease did 
not cleave proteins that did not possess DNA-binding activity. They also 
observed that strains lacking Wss1 and the HR pathway were more sensitive to 
formaldehyde compared to strains deficient in the NER pathway. Additionally, 
cells lacking Wss1 displayed higher numbers of Rad52-foci and elevated 
recombination levels when exposed to formaldehyde. These results 
demonstrated that in the absence of Wss1, recombination becomes a 
predominant DPC repair pathway. This led the authors to hypothesize that DPCs 
are repaired prior to replication by NER but that upon entering S phase, DPCs 
are repaired by HR or proteolyzed by Wss1 to facilitate translesion synthesis.  
Jentsch later conducted BLAST searches in other species for proteins with 
high sequence similarity to the Saccharomyces cerevisiae protein Wss1. In 
humans, the Spartan (SPRTN or DVC1) protein was identified. Like Wss1, 
SPRTN binds zinc and was shown to be a DNA-dependent protease linked to 
DNA replication6,94-99. Patients with mutations in the SPRTN gene suffer from an 
autosomal recessive disease called Ruijs-Aalfs syndrome (RJALS)100. 
Characteristics of this disease include premature aging, chromosomal instability, 
and early onset hepatocellular carcinoma. At the cellular level, their cells undergo 
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slower replication and show higher numbers of stalled forks and double-strand 
breaks. Ramadan et al. has proposed that SPRTN is a constitutive part of the 
replication machinery and moves with the replisome during DNA synthesis100. 
However, mice with homozygous null alleles for SPRTN die early in embryonic 
development, making it difficult discern its role in the repair of DPCs in vivo.  
The proteasome has also been investigated in DPC protein degradation. 
However, contradictory results have made its role unclear. For example, bacterial 
mutants deficient in cytosolic ATP-dependent proteases showed no effect on cell 
survival when treated with DPC-forming agents61. In Xenopus egg extracts, 
depletion of ubiquitin pools, but not proteasome inhibition, prevented DPC 
proteolysis during replication101. Baker et al. saw decreased repair of a DPC-
containing plasmid using the proteasome inhibitor MG132 in hamster cells while 
Ide et al. observed no difference in the ubiquitination of DPCs recovered from 
human cells treated with formaldehyde with or without MG13287,92. Since 
proteasome inhibitors like MG132 deplete the nuclear ubiquitin pool, it is difficult 
to resolve these discrepancies and determine whether the proteasome is directly 
involved in DPC ubiquitination/repair.  
Although progress has been made in detailing the mechanisms regulating 
DPC repair, many questions remain. Repair pathways such as nucleotide 
excision repair, homologous recombination, and proteolysis have all been 
implicated to play a role. However, it is still unknown how the cell initiates DPC 
repair of one pathway over another and whether double-strand break repair 
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pathways such as the Fanconi anemia pathway, non-homologous end-joining, 
and microhomology mediated end-joining are involved30,102-104. Fanconi anemia 
patients, who possess mutations in Fanconi anemia repair pathway, have been 
shown to be hypersensitive to DPC-inducing chemotherapeutics105-107. However, 
the involvement of the Fanconi pathway in DPC repair has yet to be 
established102. Additionally, relatively little is known about DPC repair 
mechanisms in the mitochondria. This gap in our knowledge of DPC repair could 
be used to provide insight into resistance mechanisms of DNA-damaging 
chemotherapeutics. 
 
IV. DPC REPAIR IN MITOCHONDRIA 
a. Mitochondrial genome (Table 1.1) 
The human mitochondrial genome (mtDNA) is 16 kb long and densely packed 
with genetic information encoding complexes for the electron transport chain108. It 
provides the cell with energy in the form of ATP, enzymes for lipid biogenesis, 
and is involved in other key cellular processes109. It contains one origin of 
replication on each DNA strand, two promoters (one for each strand), and lacks 
DNA histones110. Instead, mtDNA is organized into nucleoids that carries six to 
ten copies of DNA111,112. Most mitochondrial proteins are nuclear encoded and 
imported into the mitochondria113. Similar to nuclear DNA, mitochondrial DNA is 
also exposed to alkylation and hydrolytic damage, adduct formation from 
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endogenous and exogenous agents, as well as mismatched bases and strand 
breaks114.  
 
Table 1.1: Characteristic comparison of the nuclear and mitochondrial 
genome in eukaryotic cells115,116. 
Characteristic Nuclear genome Mitochondrial genome 
Size 3.3 x 109 bp 16,569 bp 
# of DNA 
molecules/cell 
46 per diploid cell Thousands/cell 
# of encoded 
genes 
20-30,000 37 




% coding DNA 3% 93% 
Transcription Genes transcribed 
individually 
All genes transcribed at the 
same time 
 
b. Mitochondrial DNA repair pathways 
Mitochondrial DNA is constantly exposed to external and internal damaging 
agents capable of forming alkylation damage, hydrolytic damage, DNA adducts, 
mismatched bases, strand breaks, and oxidative damage117-123. Because 
mitochondria are a major source of reactive oxygen species, the most well-
studied type of mtDNA damage is oxidative damage, which is repaired by the 
base excision repair pathway124-126. In 1974, Clayton et al. discovered that 
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mitochondria are unable to repair UV-induced pyrimidine dimers and lacked the 
NER pathway127. Following exposure to UV light, radioactive thymidine was not 
incorporated into isolated mitochondria from mice and human cells, and the 
damaged DNA was incapable of replication. Miyaki et al. showed that 
mitochondria were also unable to repair alkyl damage induced by two different 
carcinogens128. Double-strand break repair pathways such as homologous 
recombination and end-joining have also not been well-established in the 
mitochondria129.  
Restriction endonucleases targeted to the mitochondrial genome showed 
that yeast rely on ligase Cdc9p to repair double-strand breaks130. Work by 
Thyagarajan et al. showed that mitochondrial protein extracts catalyzed 
homologous recombination of plasmid DNA substrates in a conservative process 
that did not involve nuclease-mediated strand-annealing131. HR has also been 
shown in yeast and plant mtDNA but was only detected in low frequencies 
following exposure to endonucleases in mice132-134. Mitochondrial protein extracts 
can join blunt-ended plasmid DNA but with low efficiency135,136. Non-homologous 
end-joining also been observed in mitochondrial extracts and shown to rely on a 
C-terminally truncated form of the Ku80 end-binding protein137. Microhomology-
mediated end joining (MMEJ) of duplex oligonucleotides possessing double-
strand breaks has also been observed in mitochondrial extracts. These results 
showed that repair increased in portion to the length of microhomology and that 
the smallest amount of end-joining activity occurred with a duplex containing 5 
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nucleotides of homology on either side of the double-strand break138. While 
mitochondrial double-strand break pathways remain under investigation, other 
DNA repair pathways such as mismatch repair, single-strand break repair, and 
base excision repair have been more frequently observed in mitochondria108,139.  
 
c. Mitochondria DNA degradation 
Hundreds to thousands of copies of the mitochondrial genome is present in each 
cell. Therefore, it is reasonable that loss of mtDNA may not necessarily be 
detrimental to the cell. This turnover process involving the degradation and 
replacement of mtDNA by replication was first observed by Gross and 
Rabinowitz in 1969140. Others have shown that cells are tolerant to both chronic 
and acute mitochondrial DNA reduction as well as full elimination140-142. Thus, it is 
logical to hypothesize that degradation of severely damaged mtDNA could be 
used as a unique maintenance mechanism of the mitochondrial genome143,144. 
However, evidence for this model has yet to be directly shown and is still 
incomplete.  
 
d. DPCs in mitochondria 
DNA-protein crosslinks have been shown to form on mitochondrial DNA145. 
Enzymatic trapping of polymerases to DNA due to oxidative damage have been 
observed in purified protein and mitochondrial extracts from Hela cells. However, 
it is unclear whether DPCs also undergo proteolytic processing in the 
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mitochondria, as is hypothesized in the nucleus. The mitochondria possess their 
own E3-ubiquitin ligases, but they are located in the outer membrane and so are 
unlikely to be involved in DNA repair146. It also is unknown whether the 
translesion synthesis machinery is available in mammalian mitochondria and 
would be capable of bypassing smaller DNA-peptide crosslinks147. 
 
e. Mitochondria DNA damage and disease 
A correlation of oxidative stress and reduced mitochondria function has been 
found in several neurological disorders148,149. For example, patients with Kearns-
Sayre Syndrome have spontaneously inherited mtDNA deletions and suffer from 
cerebellar ataxia, proximal muscle weakness, and cardiac conduction 
abnormalities150. Other pathologies associated with mtDNA damage include 
diabetes, cardiovascular and liver disease, as well as aging and cancer151-154. 
Mitochondria also regulate apoptosis by controlling the translocation of pro-
apoptotic proteins from the intermediate space to the cytosol. This process can 
be inhibited in cancer cells via the overexpression of anti-apoptotic proteins. 
Mitochondria have also become an attractive target for drug therapy155-157. For 
example, doxorubicin-resistant osteosarcoma has been shown to overexpress 
the drug efflux transporter ABCB1/P-glycoprotein. However, chemically modified 
mitochondria-targeted doxorubicin was shown to decrease tumor growth, 






V. CLINICAL APPLICATIONS 
The largest class of chemotherapeutics are DNA-damaging agents which induce 
different types of DNA damage in cancer cells and interrupt the cell cycle, leading 
to cell death159-161 (Table 1.2). Within this class of drugs, crosslinking agents are 
arguably the most widely used. Crosslinking agents such as cisplatin, 
cyclophosphamide, and doxorubicin are used to treat a variety of cancers such 
as breast, brain, and prostate cancer162-164. However, cancer cells can exhibit 
resistance to these agents, resulting in therapeutic failure and patient death. It is 
known that elevated repair pathways contribute to drug resistance165,166. 
Therefore, there is a need to fill the gap of what molecular pathways are involved 
in the repair of drug-induced DNA damage. Identification of these pathways can 
lead to a better understanding of drugs resistance and the development of new 
therapies that target repair pathways167.  
DNA-protein crosslinks are one of the toxic lesions created by these 
crosslinking drugs, however, the least is known about their repair mechanisms168. 
Therefore, it is unknown how the repair of DPCs contributes to harmful side 
effects and resistance mechanisms of these drugs. Once the cellular response to 
DPC damage has been elucidated, altered expression of repair proteins can be 
examined in chemo-resistance cells. Identification of drug-resistance biomarkers 
could then be used to influence decisions in chemotherapeutic treatment or lead 
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to the development of new therapeutics that target DPC repair proteins. Inhibition 
of repair pathways involved in chemo-resistance can prevent repair, leading to 






















Table 1.2. Classification and uses of DNA-damaging chemotherapeutics169. 
Drug Type and Name Uses 
Nitrogen Mustards   
Chlorambucil Lymphocytic leukemia, lymphomas, and cancer of 
the breast and ovaries. 
Cyclophosphamide Breast cancer, prostate cancer, and non-Hodgkin’s 
lymphoma. 
Ifosfamide Testicular cancer, lymphoma, lung cancer, and 
sarcomas. 
Mechlorethamine HCl Hodgkin’s disease, solid tumors, and pleural effusion 
caused by cancer of the lung. 
Melphalan Multiple myeloma, melanoma, and cancers of the 
breast, ovary, and testes. 
Temozolomide Refractory anaplastic astrocytoma. 
Nitrosoureas   
Carmustine Hodgkin’s disease, multiple myeloma, melanoma, 
and brain tumors. 
Lomustine Advanced Hodgkin’s disease and brain tumors. 
Streptozocin Pancreatic islet cell tumor and cancer of the lung. 
Alkyl Sulfonates   
Busulfan Myelocytic leukemia. 
Alkylating-Like Drugs   
Altretamine Ovarian cancer. Also used for breast, cervix, colon, 
endometrial, head/neck, and lung cancers; 
lymphomas. 
Carboplatin Recurrent ovarian cancer. 
Cisplatin Ovarian and testicular cancer, cancer of the bladder, 
head and neck, and endometrium. 
Oxaliplatin Metastatic colorectal cancer, ovarian cancer, head 
and neck cancer, and malignant melanoma. 
Dacarbazine Metastatic malignant melanoma, sarcomas, 
neuroblastoma, and refractory Hodgkin’s disease. 












Figure 1.2. Eukaryotic transcription-coupled and global genomic nucleotide 






Figure 1.3. Eukaryotic homologous recombinational repair of a double-
strand break resolved by double Holliday junction repair or synthesis-





A Simple, Rapid, and Quantitative Assay to Measure Repair of DNA-protein 
Crosslinks Transfected into Mammalian Cells 
 
Lisa N. Chesner and Colin Campbell 









Content adapted from published article: Chesner, LN., Campbell, C. A Simple, 
Rapid, and Quantitative Assay to Measure Repair of DNA-protein Crosslinks on 
Plasmids Transfected into Mammalian Cells. J. Vis. Exp. (133), e57413, 
doi:10.3791/57413 (2018). 
 





The purpose of this method is to provide a flexible, rapid, and quantitative 
technique to examine the kinetics of DNA-protein crosslink (DPC) repair in 
mammalian cell lines. Rather than globally assaying removal of xenobiotic-
induced or spontaneous chromosomal DPC removal, this assay examines the 
repair of a homogeneous, chemically defined lesion specifically introduced at one 
site within a plasmid DNA substrate. Importantly, this approach avoids the use of 
radioactive materials and is not dependent on expensive or highly-specialized 
technology. Instead, it relies on standard recombinant DNA procedures and 
widely available real-time, quantitative polymerase chain reaction (qPCR) 
instrumentation. Given the inherent flexibility of the strategy utilized, the size of 
the crosslinked protein, as well as the nature of the chemical linkage and the 
precise DNA sequence context of the attachment site can be varied to address 
the respective contributions of these parameters to the overall efficiency of DPC 
repair. Using this method, plasmids containing a site-specific DPC were 
transfected into cells and low molecular weight DNA recovered at various times 
post-transfection. Recovered DNA is then subjected to strand-specific primer 
extension (SSPE) using a primer complementary to the damaged strand of the 
plasmid. Since the DPC lesion blocks Taq DNA polymerase, the ratio of repaired 
to un-repaired DNA can be quantitatively assessed using qPCR. Cycle threshold 
(CT) values are used to calculate percent repair at various time points in the 
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respective cell lines. This SSPE-qPCR method can also be used to quantitatively 
assess the repair kinetics of any DNA adduct that blocks Taq polymerase. 
 
II. INTRODUCTION 
 Described herein is a PCR-based assay termed Strand-Specific Primer 
Extension-Quantitative Polymerase Chain Reaction (SSPE-qPCR). The purpose 
of this method is to quantify DNA-protein crosslink (DPC) repair on plasmid DNA 
transfected into repair deficient and proficient mammalian cells. This assay is 
rapid, quantitative, extremely flexible, and directly measures repair activity. While 
this report focuses on the use of this methodology to study repair of DPCs, 
results presented below illustrate that repair of any lesion that blocks Taq 
polymerase can be studied using this methodology. 
The rationale behind the development of this method is to gain insight into 
the mechanisms through which mammalian cells repair DPCs. Unlike other types 
of DNA damage, DPCs are massively diverse.1,24 Studies have demonstrated 
that hundreds of cellular proteins can become crosslinked to DNA and that for 
each protein there are, in principle, numerous amino acid side chains that could 
become covalently attached to cellular DNA.3 In addition, there are numerous 
chemical attachment points for proteins onto the DNA backbone, including 
several positions on the nucleotide bases as well as on the ribose sugar.8,171 This 
chemical diversity raises the prospect that distinct biochemical pathways may be 
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relied upon to repair different types of DPCs. It was with this concern in mind that 
the SSPE-qPCR assay was developed.  
Several techniques have been developed to gain insight into the molecular 
biology of cellular DPC repair. The following provides an overview of the major 
approaches that have been developed, with a summary of the major strengths 
and weaknesses each possess. It is worth stressing that while this summary 
focuses on studies of DPC repair in mammalian cell culture systems, significant 
contributions to the current model of DPC repair have been made using microbial 
and cell-free systems that are not discussed in this manuscript.  
Perhaps the easiest strategy that can be taken to gain insight into the 
genetics of DPC repair is to assess the respective sensitivity to cell death 
observed in wild-type and mutant cells exposed to agents that induce DPCs.9,64 
This strategy is relatively fast, inexpensive, and doesn’t require specialized 
expertise beyond the ability to perform basic cell culture techniques. 
Counterbalancing these advantages are numerous limitations to this approach 
including the following. First, the assay does not directly measure DNA repair. 
The working assumption underlying this strategy is that inactivating mutations in 
genes encoding relevant DNA repair proteins result in an accumulation of DNA 
damage that triggers programmed cell death. However, mutations in genes 
encoding non-DNA-repair proteins could, in principal, enhance (or reduce) 
cellular sensitivity to xenobiotic-induced cell death. Second, agents that create 
DPCs invariably induce other types of DNA damage (one exception is 5-aza-2’-
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deoxycytadine, but this agent also depletes cellular methyltransferase levels172). 
Consequently, it is conceivable that enhanced cellular hypersensitivity to the 
agent in question may reflect defects in repair of interstrand crosslinks or other 
lesions. Third, as was mentioned above, DPCs represent a vastly 
heterogeneous class comprised of different types of chemical crosslinks, 
involving different protein partners. It is possible that while repair of one or more 
sub-types of these lesions may be altered in a particular genetic background, this 
difference may not be sufficient to significantly alter cellular hypersensitivity to 
death induced by this agent. In summary, while this strategy represents an 
attractive starting point, the limitations outlined above highlight the importance of 
pursuing other, more direct methods to study the kinetics of DPC repair. 
Several related approaches have been developed to achieve this 
objective. For instance, investigators have developed methods to distinguish 
between ‘free’ DNA and ‘protein-bound-DNA.173-175 Using these approaches, it is 
possible to compare steady-state levels of DPCs or following exposure to a DPC-
producing agent in different genetic backgrounds. The two strategies that have 
been most widely used involve separating DPC-containing DNA from free DNA 
using either a nitrocellulose membrane binding strategy or KCl/SDS 
precipitation.66,68 In the former approach cells are lysed and passed through a 
nitrocellulose filter. Because nitrocellulose binds protein, the filter retains protein-
linked DNA, permitting free DNA to pass through. In the latter strategy protein-
bound DNA is separated from free DNA since SDS binds to protein but not DNA, 
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and can be precipitated by addition of KCl. Consequently, protein-linked DNA 
becomes insoluble while unbound DNA remains in solution. DPC-containing DNA 
can then be quantitated using radiolabeled thymidine (if cells were initially 
metabolically labeled) or by a DNA-selective fluorescent dye like Hoechst 33258. 
These methods are reproducible and require a small number of steps. However, 
they do not provide information regarding the nature of the chemical crosslink 
through which protein is attached to DNA. Furthermore, it is important to note, 
these assays may over-estimate DPC repair by falsely scoring incomplete repair, 
i.e. proteolytic processing to smaller DNA-peptide crosslinks that may not be as 
easily trapped or precipitated, as bona fide DNA repair. 
Comet assays can be used to visualize DPC formation in cells.69 In these 
experiments, the presence of DPCs decrease DNA migration which can then be 
reversed by pretreating with proteinase K. Therefore, the length of the tail can be 
used to estimate DPC formation. However, as mentioned above, DPC-forming 
drugs create other types of DNA damage which could alter tail length. This 
protocol is also highly technical and requires expertise and training in confocal 
imaging.  
Mass spectrometry can be used to study DPC repair kinetics following 
treatment with crosslinking agents.4,17,82 These experiments treat cells with DPC-
forming agents and isolate DNA-protein crosslinks via biotin capture or phenol: 
chloroform (1:1) extraction. Mass spectrometry can then be used to identify the 
crosslinked proteins or quantitate the amount of DPCs formed over time. The 
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major advantage of this approach is the nature of the data produced. One can 
precisely catalog the types of proteins that become crosslinked following 
exposure to a xenobiotic, however, this protocol is expensive, time consuming, 
and is limited by the type of crosslink that can be detected.  
Maizels et. al developed a sensitive ‘RADAR’ (rapid approach to DNA 
adduct recovery) assay to quantitate immunodection of DNA-protein adducts as 
well as a ELISA-based RADAR assay.72,73 These assays are especially useful for 
trapping DNA-protein intermediates that transiently form in cells and generate 
samples suitable for mass spectroscopy to identify new protein adducts. This 
immunodection assay relies on the availability of antibodies to capture the DNA-
protein crosslink and, therefore, may not be capable of detecting degraded DNA-
peptide adducts that form during repair. Recently, a specific DPC repair pathway 
linked to DNA replication and a DNA-dependent metalloprotease Spartan was 
discovered in which DNA-protein crosslinks are proteolyzed to smaller peptides 
during repair. 94,176  Inherited mutations in this gene are associated with Ruijs-
Aalfs syndrome in humans, a disease characterized by genomic instability, 
premature ageing and liver cancer.22 Mice with genetically engineered Spartan 
gene defects display similar phenotypes.98,100  
Host-cell reactivation of transcriptional activity has been used to study the 
repair of defined lesions present on transfected plasmid DNA substrates.85,87 In 
these experiments, plasmid containing DPCs (or other types of DNA lesions) that 
block the transcription of a reporter, such as luciferase, are transfected into cells. 
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Luminescence measurements taken 24-72 h later are then correlated with DPC 
repair.  However, these indirect repair assays are incapable of detecting repair 
events earlier than 24 h post-transfection and cannot distinguish between RNA 
polymerase bypass of partially repaired substrates and complete repair.  
Each of the methods described above has advantages and has 
contributed to the current model of DPC repair. However, the SSPE-qPCR assay 
circumvents several of the limitations associated with these other approaches 
and consequently can provide more specific insight into DPC repair mechanisms. 
For example, the SSPE-qPCR assay can directly measure repair of site-specific 
DPCs on DNA in intact mammalian cells. This method is versatile and has been 
used to obtained repair results following transfection in hamster and human cell 
lines. Transfection of the plasmid can be performed using lipofection or 
electroporation in cultured mammalian cell lines. It also ensures that only repair 
of defined DNA-protein crosslinks is measured and not other types of DNA 
damage induced by most DPC-forming agents. The SSPE-qPCR is easy to 
perform, inexpensive, and rapid. Results obtained using this assay have detected 
repair events as early as 2 h post-transfection. Using this method, variables that 
may influence DPC repair outcomes can be studied in a manner that is sensitive 
and efficient. For example, the role of transcription in DPC repair has yet to be 
rigorously evaluated. Due to the flexibility of the SSPE-qPCR assay, the 
crosslinking site of the DPC can be manipulated to address this question. In 
addition, introduction of an origin of replication into the DPC-bearing plasmid can 
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be used to address the influence of replication on DPC repair. Additionally, 
multiple crosslinks can be created on the plasmid to examine differences in 
repair of a single DPC versus multiple crosslinks. These are questions that would 
be difficult to answer using chromosomal DNA but can easily be addressed using 
the SSPE-qPCR assay. Overall, the SSPE-qPCR assay requires purified, 
plasmid DNA in microgram quantities containing a lesion of a known location. 
Adducts besides DPC can be used in this assay, however, the lesion must be 
capable of blocking extension by Taq polymerase.  
 
III. PROTOCOL 
1. Generation of DPC-containing plasmid DNA  
1.1) Combine 80 pmol of oligonucleotide containing an 8-oxoguanine residue (20 
µL) with 10 units of T4 polynucleotide kinase (1µL) in 10X ligase buffer (5 µL). 
Add water to reach a total volume of 50 µL and incubate at 37 °C for 30 min in a 
heated water bath.   
1.1.1) Combine the phosphorylated oligonucleotide (50 µL), 80 pmol of single-
stranded DNA (80 µL), 100 units Taq polymerase (20 µL) in 10X Taq reaction 
buffer (25 µL), 100 mM ATP (20 µL), 10 mM dNTPs (20 µL), NEB buffer 2 (25 
µL), and 8 µg BSA (20 µL) to total 260 µL. Incubate the sample in a PCR 
machine set at 75 °C for 15 min followed by 37 °C for 5 min. Next, add 60 units of 
T4 polymerase (20 µL), 8000 units ligase (20 µL), 100 mM ATP (20 µL), 10 mM 
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dNTPs (20 µL), NEB buffer 2 (15 µL), and 8 µg BSA (20 µL) to total 375 µL. 
Incubate the reaction overnight at 37 °C (Figure 2.1A).  
1.2) Create a 50:50 buffer-saturated phenol: chloroform mixture. Add equal 
volumes of each component, mix, and spin in a table-top centrifuge at 15K x g for 
5 minutes. Chloroform drives water out of the buffer-saturated phenol to form two 
layers: an upper, aqueous layer and a bottom, organic layer. Add 375 µL of the 
lower, organic layer to the primer extension reaction, mix, and spin in a table-top 
centrifuge at 15K x g for 5 minutes. CAUTION: Phenol and chloroform are 
hazardous substances and precautions should be taken to avoid contact with the 
eyes or skin. 
1.2.1) Following centrifugation, carefully extract the top layer and mix with 
ammonium acetate added to a final concentration of 0.3 M followed by 2 volumes 
of 100% ethanol. Store the solution at -20°C for a minimum of 30 minutes or 
overnight.  
1.2.2) Spin the sample in a table-top centrifuge at 15K x g at 4°C for 10 min. 
Remove the supernatant and wash the pellet in 1 mL of 70% ethanol. Spin the 
sample in a table-top centrifuge at 15K x g at 4°C for 5 min. Remove the 
supernatant and resuspend the pellet in 100 µL of water.  
1.3) Combine 50 µL of DNA from the previous step with 16 µL 6X gel-loading 
dye, and 34 µL water and subject to electrophoresis on a 0.8% low-melt agarose 
gel containing 0.5 µg/mL ethidium bromide. Run the gel at 2 V/cm on a 10-cm gel 
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for 6 h in 1X TAE buffer. Excise the supercoiled band using a razor blade and 
weigh the gel slice (Figure 2.1A). Note: It can be helpful to run a positive control 
to serve as a marker for where the covalently closed, supercoiled DNA migrates. 
CAUTION: Ethidium bromide is a mutagen and precautions should be taken to 
avoid contact with the skin. Also, it is important to minimize the time that the 
plasmid sample is exposed to UV to reduce the formation of UV photoproducts. 
1.3.1) Digest the gel slice by adding 10% β-agarase reaction buffer for every mg 
of gel weight. Incubate at 65 °C for 10 min and cool to 42 °C. Add 10 units of β-
agarase and incubate at 42 °C for 1 h.  
1.3.2) Following incubation, measure the volume and add ammonium acetate to 
a final concentration of 0.3 M and chill on ice for 15 min. Centrifuge at 15K x g for 
15 min at room temperature, collect the supernatant, and add 2 volumes of 
isopropanol. Chill at -20 °C overnight.  
1.3.3) Centrifuge the purified, supercoiled DNA for 10 min at 15K x g in a table-
top centrifuge at 4 °C and resuspend the pellet in 40 µL of water.  
1.4) Crosslink 12 pmol (15 µL) of DNA to 36 pmol of oxoguanine glycosylase (1 
µL) in buffer containing 100 mM NaCl (3 µL), 1 mM MgCl2 (3 µL), 20 mM Tris-HCl 
pH 7.0 (6 µL), and 10 mM sodium cyanoborohydride (2 µL) to reach a final 
volume of 30 µL at 37 °C for 30 min.177 Remove 1 µL of crosslinked sample and 




2. KCl/SDS precipitation 
2.1) To visualize crosslinking efficiency, restriction digest 1 µg of the crosslinked 
plasmid with 1 µL BspDI in 10x buffer at 37 °C for 1 h to generate two different 
sized DNA fragments. One fragment will be crosslinked to protein (4.4 kb) and 
the other will not (2.8 kB), (Figure 2.1B). 
2.1.1) Divide the samples in half, add SDS to both to a final concentration of 
0.5%, and incubate at 65 °C for 10 min. 
2.1.2) Add KCl (final concentration 100 mM) to one of the samples and incubate 
on ice for 5 min. 
2.1.3) Centrifuge both samples at 12K x g for 5 min at 4 °C and run the 
supernatants on an agarose gel to estimate percent conjugation of protein to 
DNA.66 Note: KCl/SDS precipitation is used for quality control, not substrate 
preparation. 
 
3. Transfection into mammalian cells 
3.1) One day prior to transfection, plate 0.5 X 106 cells/well in a 6-well plate. The 
next day, mix 1.5 µg (30 µL) of the DPC-containing plasmid (from step 1.6) with 
300 µL of serum-free culture media. In another tube, mix 12 µL of lipofectamine 
reagent and 300 µL of serum-free culture media. Combine 300 µL of diluted DNA 
with 300 µL of diluted lipofectamine and incubate for 5 min at room temperature. 
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Add 250 µL of the complexes to each of two wells and allow to incubate for a 
minimum of 1 h. 
3.1.2) Following incubation, remove media, add 1 mL of 0.6% SDS/0.01 M 
EDTA, and incubate at room temperature for 10-15 min. Scrape the cells using a 
rubber policeman and transfer to a 1.5 mL microfuge tube. Add 200 µL of 5 M 
NaCl (final concentration of 1 M), invert gently 5 times, and incubate at 4 °C 
overnight.178 
3.1.3) Centrifuge the samples at 15K x g in a table-top instrument at 4 °C for 30 
min, collect the supernatant, ethanol precipitate as described above, and 
resuspend in 50 µL of water.  
 
4. Strand-specific primer extension-qPCR 
4.1) Mix together 1 µL of recovered DNA from each time point (including 0 hr), 2X 
sybr green master mix (30 µL), 27 µL of water, and 1 µL (100 pMol) of primer 
complementary to the damage strand of the plasmid (Primer R, Figure 2.2). 
Perform PCR using the following conditions: Initial pre-melt for 10 min at 90 °C, 
followed by 8 cycles of:  90 °C, 15 seconds, 65 °C, 1 minute. At the completion of 
cycle 8 add 1 µL (100 pMol) of the second primer to total 60 µL (Primer L, Figure 
2.2).179 (see Table of Materials for reagent details) 
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4.1.2) Mix 1 µL of unamplified recovered DNA from each time point (including 0 
hr), 2X sybr green master mix (30 µL), 27 µL of water, and 1 µL of each primer 
(100 pMol) to total 60 µL.  
 
4.1.3) Load a 96-well PCR plate with the samples from 4.1 and 4.2 (20 µL/well, in 
triplicate) and perform qPCR for 30 cycles using the conditions described above. 
4.1.4) Average the CT values from each set of triplicate samples. Subtract the 
CT values generated in 4.1 from 4.2 to obtain the delta CT value for each 
sample. Subtract the 0 h time point from the delta CT value to remove any 
background. (See Representative Results section for a detailed description.) 
4.1.5) Convert the delta CT value into percent repair using the formula: percent 
repair=(2ΔCT/23) x 100.  
 
IV. REPRESENTATIVE RESULTS  
To utilize the SSPE-qPCR assay to assess cellular DPC repair a sufficient 
quantity (µg amounts) of high-quality DPC repair substrate must be prepared. To 
obtain this product, an oligonucleotide containing an 8-oxoguanine residue was 
annealed to complementary single-stranded DNA, primer extended, and gel 
purified to ensure that only covalently, closed circular product was used for 
transfections (Figure 2.1A). This report focuses on substrates in which 
borohydride-trapping is used to create a covalent crosslink between recombinant 
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human oxoguanine glycosylase and a ribose unit on a double-stranded circular 
plasmid molecule, although analogous approaches can be used to obtain 
chemically diverse DPC substrates. The oxoguanine glycosylase/borohydride 
trapping strategy is especially attractive given the extremely high efficiency of the 
crosslinking reaction. As shown in Figure 2.1B, KCl/SDS precipitation performed 
on a DPC substrate that had been digested into two fragments selectively and 
nearly quantitatively depleted the DNA fragment harboring the DPC. These 
results support the conclusion that essentially 100% of the plasmid substrate 
molecules contain a protein crosslink.  
The SSPE-qPCR assay described in the Protocols section utilizes cycle 
threshold (CT) values generated by qPCR to calculate the percent of DPC repair 
following transfection in mammalian cells. As Figure 2.2 illustrates, the protein 
crosslink blocks Taq polymerase from extending the ‘R’ primer annealed to the 
DPC-containing strand. A second, critical feature of this assay is the 
incorporation of eight rounds of strand-specific primer extension (SSPE) 
reactions (using the R primer) prior to performing the qPCR assay. While 
undamaged (or repaired) DNA will be extended during these SSPE reactions, 
creating a binding site for the downstream ‘L’ primer, damaged DNA (or 
incompletely repaired DNA) will not be extended. Consequently, SSPE increases 
the abundance of each undamaged (or repaired) strand by eight-fold. This 
means that repaired samples in which the SSPE step has been performed prior 
to qPCR will display a cycle threshold (CT) value that is three units lower than 
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that obtained for an identical sample in which SSPE was not performed prior to 
qPCR (Figure 2.2). The three-unit difference in CT values observed for the two 
treatments, referred to as Δ CT, reflects the fact that 8=23. This delta CT value 
can be used to calculate cellular DNA repair activity by using the formula: percent 
DNA repair= (2ΔCT/23) X 100. Control experiments confirmed that a delta CT 
value of approximately 3 was consistently observed when undamaged substrate 
plasmids were subjected to SSPE-qPCR (data not shown). 
Table 2.1 depicts example CT values that were generated from DPC-
containing plasmid substrates that were recovered from Chinese hamster lung 
fibroblasts 3 and 8 h post-transfection (A), as well as from time zero samples, i.e. 
samples that were prepared as described in the Protocol section, but not 
transfected into cells (B). The table also provides the ΔCT, and percent repair 
values (calculated using the formula 2ΔCT/23x 100) obtained from these samples. 
As illustrated in Table 2.1A, the percent repair calculated from samples 
harvested 3 and 8 h post-transfection was 66% and 93%, respectively. These 
values are then subtracted from that obtained from analysis of the 0 h sample to 
determine percent repair. Table 2.1B depicts CT values for two different 0 hr 
samples in which efficient crosslinking was or was not achieved prior to 
transfection. Efficiently crosslinked sample resulted in a delta CT value of 0.8 
whereas a poorly crosslinked sample resulted in a delta CT value of 2.5. To date, 
it has not been possible to precisely determine the source of the 0.8 background 
signal in the efficiently crosslinked 0 h sample. It is unlikely that this background 
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reflects a low level of either spontaneous DPC removal, or is due to a low level of 
Taq polymerase ‘bypass’ synthesis through the DPC lesion. Because extensive 
experimentation performed on highly purified single-stranded M13 substrate 
consistently yielded a delta CT value of approximately 0.8, i.e. essentially 
identical to this ‘background’ extension seen in DPC-containing substrates. 
Consequently, it is likely that there is a small degree of mis-priming of the ‘R’ 
primer during SSPE that results in the generation of a small amount of product 
that can subsequently be amplified when the ‘L’ primer is added and qPCR 
performed. Efforts to eliminate this background by manipulating PCR conditions 
have, to date, failed to remedy this defect. However, the subtraction strategy 
described above permits one to accurately estimate DPC repair activity. It is 
worth noting that inefficient crosslinking of the protein onto the plasmid will result 
in an elevated background value. This is depicted in the sample data provided in 
Table 2.1B where inefficient protein-DNA crosslinking resulted in a higher delta 
CT value for time 0. Therefore, control experiments are invariably performed prior 
to initiating transfections and substrates with delta CT values elevated above the 
0.8 threshold level are discarded. As mentioned in the qPCR protocol, each 
sample is divided into 3 wells to ensure pipetting consistency. These replicates 
are then averaged to obtain the CT value for that sample. Replicates that deviate 
more than +/- 0.1 are eliminated from the data set. If all three replicates deviate 
more than +/- 0.1 from each other, the SSPE-qPCR assay is redone until 
consistent values are obtained. Experience shows that at least 3 independent 
	
43	
transfections must be performed to obtain reliable average values that can then 
be subjected to statistical analysis to determine the influence of various 
parameters on DPC repair efficiency.   
 
 
Table 2.1: Calculating percent repair using CT values generated from 
SSPE-qPCR. (A) Repair of a DPC-containing substrate transfected in V79 
Chinese hamster lung fibroblasts 3 and 8 h post-transfection. (B) SSPE-qPCR of 
0 h samples not transfected into cells. In one sample the efficiency of the 
crosslinking reaction between DNA and oxoguanine glycosylase was high (this 
sample yielded a low delta CT value) while in the other sample the efficiency of 
protein crosslinking was low (this sample yielded a relatively high delta CT 
value).  See text of Representative Results for details. 
Table A 
	 	 	 	
Time - Primer extension 
+ Primer 
extension Δ CT 
Percent Repair 
(2ΔCT/23x 100)  
3 h 23.5 21.1 2.4 66 
8 h 29.4 26.5 2.9 93 
	 	 	 	 	Table B 
	 	 	 	
Time - Primer extension 
+ Primer 
extension Δ CT 
Percent 
Background 
(2ΔCT/23x 100)  
0 h 15.4 14.6 0.8 22 




V. DISCUSSION  
The strand-specific primer extension-qPCR method offers numerous 
advantages over other approaches by examining the repair of a homogenous 
population containing a single, defined DPC lesion. It is noteworthy that in 
addition to controlling the identity of the protein and the type of chemical crosslink 
used to connect the protein to the DNA, one can easily manipulate the sequence 
context into which the DPC lesion is introduced. We have explored the influence 
on DPC repair of introducing the lesion on either the template or coding strand of 
a plasmid downstream of an active promotor locus. Similarly, we are in the 
process of investigating the influence on DPC repair of replication using a M13 
plasmid containing an SV40 origin of replication transfected into HEK293T cells. 
The assay described herein directly measures DPC repair, as opposed to other 
strategies such as host cell reactivation that indirectly estimates repair 
activity.85,87 In addition, the system is robust, sensitive, and quantitative. Unlike 
other systems, which measure DPC removal, this assay only detects complete 
repair events, i.e. it requires not only that the DPC lesion be removed but that the 
integrity of the duplex DNA be fully restored.82 This is because abasic sites and 
nicks or breaks in the phosphodiester backbone block the assay as effectively as 
the original DPC lesion.180  
While this report focuses on a particular type of DPC which was created 
by borohydride trapping of an enzyme reaction intermediate, we are currently 
developing approaches to study repair of DPCs involving other proteins and 
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lesions in which the protein linkage to the DNA occurs through the nucleoside 
base, rather than the ribose position. Using reductive amination, we have created 
protein and peptide crosslinks attached to the guanine or cytosine base of a DNA 
primer.181 These oligonucleotides were purified to homogeneity and used to 
generate supercoiled plasmids containing DNA-protein and DNA-peptide 
crosslinks. While the efficiency of these reactions is somewhat reduced relative 
to that of the oxoguanine glycosylase crosslink approach described in detail 
above, they were nevertheless successful and permit us to examine the repair of 
these substrates in wild-type and nucleotide excision repair-deficient mammalian 
cell lines. We have also used the SSPE-qPCR assay to study the repair of 
oxoguanine lesions and a synthetic ribose-cholesterol conjugate, which was 
previously shown to be repaired via the cellular nucleotide excision repair 
machinery.182 As Figure 2.2 graphically depicts, repair of any lesion that blocks 
primer extension by Taq polymerase can, in principle, be measured using the 
SSPE-qPCR assay. 
Current models of DPC repair suggest that larger DNA-protein crosslinks 
(>10 kDa) are subjected to proteolytic processing to smaller peptide lesion prior 
to removal.183-185 Most likely candidates responsible for this proteolysis are the 
proteasome or a specific protease in human cells named Spartan.6,93,94,97,101,176 
Further investigations into the roles of these proteases can be conducted using 
the SSPE-qPCR assay. Proteasome inhibitors could be used to pretreat cells 
prior to transfection with DPC-containing substrates. Alternatively, Spartan 
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knockdown cell lines could be transfected with damaged plasmids to elucidate its 
role in proteolysis of larger DPCs.  
Irrespective of the method used to create the crosslink or of the nature of 
the DNA lesion, it is worth stressing that the SSPE-qPCR methodology is 
critically dependent on the ability to generate substantial amounts of 
homogeneous DPC-plasmid substrate. Steps essential for this analysis include 
purification of covalently, closed-circular plasmid following primer extension to 
eliminate any nicked or linear plasmid molecules. These contaminants must be 
eliminated to ensure that any subsequent DPC repair observed is not due to 
nick-directed or double-strand break-directed repair processes. Failure to obtain 
sufficient quantities of supercoiled DNA following primer extension reactions may 
be overcome by varying the ratio of oligonucleotide to single-stranded DNA. 
Another important step for the SSPE-qPCR method, is the crosslinking efficiency 
of the protein to the plasmid. In this study, an efficient, enzymatic reaction was 
used to crosslink the oxoguanine glycosylase protein to an 8-oxo-guanine lesion. 
Sub-optimum crosslinking can be improved by varying the amount of protein 
added to the reaction.  
While the results described in this report relied on lipofection to introduce 
DPC repair substrates into recipient cells, there is no reason, a priori, other 
transfections methods could not be employed. We have performed preliminary 
studies and observed that electroporation39 can also be used. However, it is 
worth noting that in our experience, electroporation transfection efficiency is 
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reduced compared to lipofection, and we found it necessary to use carrier DNA 
(up to 5 µg) in addition to the 1.5 µg of DPC substrate to obtain repair data. 
Overall, the SSPE-qPCR method described above provides an innovative way to 
exclusively examine DPC repair on plasmid DNA and generate new insight into 





Figure 2.1. Generation of a DPC-containing plasmid. (A) An oligonucleotide 
containing an 8-oxo-guanine residue (red) is annealed to single-stranded DNA 
(bold black circle) and extended to create double-stranded plasmid (primer 
extension product indicated by dashed line). Following electrophoresis in 
ethidium bromide, the band corresponding to supercoiled DNA (red box) is 
excised from a low-melt agarose gel and digested with b-agarase. Lanes: (1) 
Molecular weight marker, (2) single-stranded DNA, (3) double-stranded DNA, (4) 
primer extended sample. (B) Oxoguanine glycosylase (abbreviated hOGG1, 
depicted as an orange circle) is crosslinked to the 8-oxo-guanine residue via 
sodium cyanoborohydride and the resulting DPC substrate digested to generate 
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a 2800 base pair free DNA fragment and a 4400 base pair fragment attached to 
the protein. SDS is added to the sample which is then divided into two portions, 
one of which is treated with KCl and centrifuged to sediment DPC-containing 
DNA (depicted as an orange pellet). The supernatant from this latter sample 
(depicted as blue fluid in centrifuge tube) and the sample not exposed to KCl are 
subjected to gel electrophoresis. Lanes: (1) Molecular weight marker, (2) –KCl, 










Figure 2.2: Quantification of damaged plasmid via strand-specific primer 
extension-qPCR (SSPE-qPCR). Plasmid DNA is denatured and a primer 
complementary to the damaged strand (R) is annealed and extended. This 
process is repeated for a total of 8 cycles. With a damaged substrate (top), Taq 
polymerase is blocked by the DPC lesion and will not produce full length product 
strands. In contrast, with a repaired substrate (bottom), Taq polymerase will 
produce full-length product strands containing the binding site for primer L. After 
8 cycles, primer L is added and cycle threshold values determined using qPCR. 
Example amplification results for damaged and undamaged substrates are 
illustrated on the right with the red line representing DNA that underwent primer 
extension prior to qPCR and blue representing DNA that was not primer 
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DNA-protein crosslinks (DPCs) are complex DNA lesions that induce 
mutagenesis and cell death. DPCs are created by common antitumor drugs, 
reactive oxygen species, and endogenous aldehydes. Since these agents create 
other types of DNA damage in addition to DPCs, identification of the mechanisms 
of DPC repair is challenging. In this study, we created plasmid substrates 
containing site-specific DPC lesions, as well as plasmids harboring lesions that 
are selectively repaired by the base excision or nucleotide excision repair (NER) 
pathways. These substrates were transfected into mammalian cells and a 
quantitative real-time PCR assay employed to study their repair. This assay 
revealed that DPC lesions were rapidly repaired in wild-type human and Chinese 
hamster derived cells, as were plasmids harboring an oxoguanine residue (base 
excision repair substrate) or cholesterol lesion (NER substrate). Interestingly, the 
DPC substrate was repaired in human cells nearly three times as efficiently as in 
Chinese hamster cells (>75% vs ∼25% repair at 8 h post-transfection), while 
there was no significant species-specific difference in the efficiency with which 
the cholesterol lesion was repaired (∼60% repair). Experiments revealed that 
both human and hamster cells deficient in NER due to mutations in the 
xeroderma pigmentosum A or D genes were five to ten-fold less able to repair 
the cholesterol and DPC lesions than were wild-type control clones, and that both 
the global genome and transcription-coupled sub-pathways of NER were capable 
of repairing DPCs. In addition, analyses using this PCR-based assay revealed 
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that a 4 kDa peptide DNA crosslink was repaired nearly twice as efficiently as 
was a ∼38 kDa DPC, suggesting that proteolytic degradation of crosslinked 
proteins occurs during DPC repair. These results highlight the utility of this PCR-
based assay to study DNA repair and indicate that the NER machinery rapidly 
and efficiently repairs plasmid DPC lesions in mammalian cells. 
 
II. INTRODUCTION 
DNA-protein crosslinks (DPCs) are unusually bulky lesions formed upon 
covalent trapping of proteins on DNA strands 24. These helix-distorting 
complexes are mutagenic, toxic, and are able to block essential cell processes 
such as transcription and replication 168,186. Proteins of various sizes and 
functions can become crosslinked to DNA via multiple mechanisms 17,82. For 
example, endogenous DPCs can be formed by the trapping of repair proteins 
recruited to sites of DNA damage or as a byproduct of lipid peroxidation of 
reactive oxygen species in the blood 15,171,187,188. Exogenous agents such as 
ionizing radiation, UV light, cigarette smoke, and chemotherapeutics such as 
cisplatin also create DPCs 1,3,8,9,17,189,190. Despite their common occurrence and 
cytotoxic effects, the exact mechanism(s) by which DPCs are repaired is still not 
well understood.  
In order to gain insight into the repair mechanism of DNA-protein 
crosslinks, DPC-forming agents have been used to assess hypersensitivity in 
repair mutants 1. Results from these experiments have provided evidence for the 
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roles of nucleotide excision repair (NER) and homologous recombination (HR) in 
DPC repair 61. However, there are contradictory reports in the literature regarding 
the relative contributions of the two repair pathways. Specifically, genetic studies 
performed in Escherichia coli revealed that uvrA and recA mutants deficient in 
NER or HR were hypersensitive to the DPC-inducing agent formaldehyde 33,34. 
However, only recA and not uvrA mutants were hypersensitive to DPCs induced 
by azacytidine 191,192. In Saccharomyces cerevisiae, mutants deficient in NER, 
but not HR, were sensitive to formaldehyde 60,62. Similarly, human cells from 
xeroderma pigmentosum patients possessing mutations in the NER pathway 
were sensitive to DPC-inducing agents 63,64.  
Since all known DPC-forming agents induce other types of DNA damage, 
such as DNA monoadducts and DNA-DNA cross-links, it is difficult to conclude if 
sensitivity to these drugs is influenced by lesions other than DPCs. In an effort to 
overcome this potential limitation, investigators have directly examined the 
kinetics of DPC formation and removal from wild-type and repair-deficient clones 
following exposure to DNA damaging agents 193. However, these studies have 
yielded contradictory results. For example, Quievryn et al. failed to detect 
differences in the kinetics of formaldehyde-induced DPC removal between NER-
deficient human fibroblasts and control 194. Conversely, DPCs induced by 
nornitrogen mustard accumulated at higher rates in human cells deficient in the 
NER gene XPA compared to HR-deficient or wild-type clones 82.  
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To more directly assess the involvement of NER in DPC repair, Minko et 
al. incubated DPC-containing oligonucleotides with UvrABC nucleases from 
Escherichia coli and saw slower incision rates of DNA containing a 16 kDa 
protein compared to smaller DNA-peptide crosslinks 183,184. In vitro studies 
performed with human nucleases saw similar results where 4 and 12 amino acid 
peptide-crosslinks were recognized by the NER machinery but were unable to 
remove a 16 kDa protein-crosslink 185. Nakano et al. later reported a size limit of 
8-10 kDa for the excision of crosslinked proteins by NER in mammalian cells 
while Baker et al. saw NER-directed repair of a 38 kDa attached to plasmid DNA 
87,92. Currently, the role of NER in the repair of DPCs (specifically those 
consisting of proteins larger than 10 kDa) remains unclear. However, it is 
hypothesized that the decreased efficiency of NER to repair larger protein-
crosslinks is caused by steric hindrance of damage recognition proteins and 
suggests that proteolytic degradation is necessary prior to repair. While it was 
originally proposed that the proteasome is responsible for proteolysis of full size 
DPCs, more recent studies have suggested that a different protease (Spartan in 
humans) is involved 6,93,94,97,101,176.  
To clarify the role of NER in the repair of DPCs in mammalian cells, as 
well as to address more specific questions regarding how size and location 
influence DPC repair, we employed a PCR-based assay we term Strand-Specific 
Primer Extension-Quantitative Polymerase Chain Reaction (SSPE-qPCR). This 
assay is capable of quantifying the repair kinetics of a broad range of lesions 
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present on plasmid DNA transfected into repair deficient and corrected 
mammalian cells. This assay provides significant advantages over previously 
utilized approaches in that it is rapid, highly quantitative, and extremely flexible. 
Importantly, this method directly measures repair activity, in contrast to other 
plasmid-based strategies that rely on indirect measures such as host-cell 
reactivation of gene function. Results from our initial analyses provide new 
insight into the ability of the global genome and transcription-coupled NER 
pathways to repair DPCs in hamster and human cells.  
 
III. MATERIAL AND METHODS 
Materials 
Chemicals and enzymes. Oligodeoxynucleotides (ODNs) containing 8-
oxo-2’-deoxyguanosine (8-oxo-dG) or cholesterol modifications were obtained 
from Midland Certified Reagent (Midland, TX). All other ODNs were purchased 
from the University of Minnesota Genomic Center. Human oxoguanine 
glycosylase 1 (OGG1) was expressed and purified from BL21(DE3) bacteria 
(Thermo Fisher) using a pET-28a expression vector 13. Single-stranded M13 
vector and all enzymes were obtained from New England Biolabs (Beverly, MA) 
unless specified otherwise. Chemicals were purchased from Sigma Chemical (St. 
Louis, MO) unless indicated. 
Cell lines. Chinese hamster lung fibroblast cell lines V79 (GM16136) and 
V-H1 (GM16141) were obtained from the Coriell Institute for Medical Research 
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(Camden, NJ). V79 are wild-type cells from which the V-H1 clones were derived 
following an ethylnitrosourea-induced mutagenesis screen 195-197. V-H1 cells 
belong to nucleotide excision repair complementation group 2 and lack a 
functional XPD gene 198. These cells are deficient in the ERCC2 gene, which 
codes for the XPD protein involved in the helicase activity that unwinds duplex 
DNA during nucleotide excision repair 198. Chinese hamster lung fibroblast cells 
were cultured in Ham’s F-12 modified essential Eagle’s media (Life 
Technologies, Grand Island, NY) supplemented with 9% fetal bovine serum 
(Atlanta Biologics, Atlanta, GA). Chinese hamster ovary CHO-K1 cells were a 
kind gift from Professor Harry Orr (University of Minnesota). Immortalized human 
dermal fibroblasts from xeroderma pigmentosum patients with inactivating 
mutations in the NER XPD gene (GM08207) or XPA gene (GM04312), as well as 
gene-corrected clones (GM15877 and GM15876, respectively) derived from 
these lines were obtained from the Coriell institute. Human and CHO-K1 cells 
were cultured in Dulbecco’s modified Eagle’s media (Life Technologies, Grand 
Island, NY) supplemented with 9% fetal bovine serum. All cells were maintained 








Table 3.1. Oligodeoxynucleotides (ODNs) used is this study (5’à3’). 
ODN Sequence Use 

















M13 Primer R CGGCTCGTATGTTGTGTG qPCR of M13 
plasmid 
M13 Primer L GCTGCAAGGCGATTAAGT qPCR of M13 
plasmid 
RSV-Zeo 1 TATCCGAGATCCGAGGAA Topo 2.1 PCR 
Cloning Kit 








CCGGTCGGTCCAGAACTC qPCR of M13-
Zeo plasmid 
Primer C GGCCAACATGGCCAA Taq extension 
assay 
Primer Z GGTGTGCACCTCCAA Taq extension 
assay 
Zeo F1 CAAGTTGACCAGTGCCGTTC RT PCR 
Zeo R1 TGATGAACAGGGTCACGTCG RT PCR 
Abasic 
complement 












Taq polymerase extension assay. To confirm that Taq polymerase permanently 
stalls at abasic sites (and by extension, lesions attached to abasic sites) 200 
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pmol of the oligodeoxynucleotide M13-RSV-Zeo-8oxo (template) was annealed 
to 200 pmol of primer C (Table 3.1) in restriction enzyme buffer 2 (New England 
Biolabs) and water in a volume of 10 µL at 95°C for 5 minutes and slowly cooled 
to room temperature. The creation of a duplex is necessary because OGG1 
protein will not react with single-stranded DNA. The duplex DNA was then 
incubated in the presence or absence of OGG1 (200 pmol) in buffer containing 
100 mM NaCl, 1mM MgCl2, and 20 mM Tris-HCl pH 7.0 at 37°C (final volume 15 
µL) for 30 minutes. Samples incubated with OGG1 excise the 8-oxo-dG residue 
leaving an abasic site at its position. Each sample was divided in half and 
incubated in the presence or absence of primer Z (100 pmol, Table 3.1) with 10 
mM dNTPs (Thermo Scientific), Taq reaction buffer (New England Biolabs), and 
Taq polymerase (20 units) in a final volume of 10 µL at 95°C for 5 minutes. 
Samples were then slow cooled to 75°C for 15 minutes, resolved on a NuPAGE 
12% Bis-Tris Gel (Invitrogen) at 18V/cm at 55°C, and stained with ethidium 
bromide. 
 
Construction of plasmid DNA repair substrates. Synthetic oligodeoxynucleotides 
(80 pmol) containing either cholesterol (NER positive control) or 8-oxo-dG 
modifications (M13-cholesterol or M13-8oxo, Table 1) were phosphorylated with 
T4 PNK (10 units) in ligase buffer (New England Biolabs) for 30 minutes at 37°C 
in a total volume of 50 µL. Phosphorylated oligonucleotides were then annealed 
to single-stranded M13 (8 pmol), extended with Taq polymerase (100 units), Taq 
	
60	
reaction buffer (New England Biolabs), 100 mM ATP (Teknova), 10 mM dNTPs 
(Thermo Scientific), restriction enzyme buffer 2 (New England Biolabs), and 8 µg 
bovine serum albumin for 15 minutes at 75°C in 260 µL. The temperature was 
then lowered to 37°C at which point T4 polymerase (60 units) and T4 ligase 
(8000 units) were added and the reaction incubated at 37°C overnight in 375 µL 
(Figure 3.2). Extension products were resolved on a 0.8% low melting 
temperature agarose gel. Supercoiled DNA was excised with a razor blade, 
digested with β-agarase (10 units) according to manufacturer’s protocol, purified 
by phenol: chloroform extraction and ethanol precipitation, and resuspended in 
water. DNA containing an 8-oxo-dG residue (0.36 pmol) was crosslinked to 
OGG1 (36 pmol) in buffer containing 100 mM NaCl, 1 mM MgCl2, 20 mM Tris-
HCl pH 7.0, and 10 mM sodium cyanoborohydride at 37°C for 30 minutes 177,199. 
During this reaction, the 249K active residue attacks the C1 position of the 8-oxo-
dG lesion, expelling the base to create an abasic site. Addition of sodium 
cyanoborohydride reduces the intermediate Schiff base formed, trapping the 
protein to the ribose (Figure 3.4). To study of the effect of protein size on DPC 
repair efficiency, DPC substrates created as described above were exposed to 
0.5 µg of trypsin (Promega) at 37°C in 50 mM Tris-HCl pH 8 overnight prior to 
transfection. Molecular weight of the digestion product was confirmed by 
crosslinking 500 pmol (1µL) of OGG1 protein to 500 pmol of duplex oligo 
containing an 8-oxo-dG modification using the same conditions stated above. 
This material was subsequently treated with 5 µg trypsin (10 µL) in 50 mM Tris-
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HCl pH 8 buffer (20 µL) overnight at 37°C, followed by addition of 10 U DNASE I 
(5 µL) in DNASE I buffer (15µL) at 37°C for 30 minutes. This material was 
subsequently resolved on a 16% Tris-Tricine Gel (Bio-Rad) and stained with 
simply blue (Invitrogen).  
 
KCl/SDS precipitation of DNA-protein crosslinks. To confirm the presence of the 
OGG1 protein crosslink, lesion-containing M13 plasmids (prepared as described 
above) were digested with BspDI for 1 hour at 37°C to generate two restriction 
fragments, one containing the DPC (4.4 kb) and a second, protein-free fragment 
(2.8 kb). The digest was treated with SDS at a final concentration of 0.5% and 
incubated at 65°C for 10 minutes to facilitate protein binding. The samples were 
then divided in two, and KCl (final concentration 100 mM) was added to one 
sample and omitted from the other. The reactions were incubated on ice for 5 
minutes followed by centrifugation at 12K x G for 5 minutes at 4°C 66. The 
supernatant from both samples was resolved by agarose gel electrophoresis and 
stained with ethidium bromide. Crosslinking efficiency was determined by 
scanning densitometry using ImageJ to determine the amount of plasmid DNA 
recovered from solution following KCl/SDS precipitation, as depicted in Figure 
3.5.  
 
Cloning of a transcriptional unit into M13mp18. Two pg of plasmid psF-CMV-
RSV-Zeo Asc1 (Sigma) was amplified with RSV-ZEO 1 and 2 primers (1µM, 
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Table 1) using Pfu Master Mix (G-Biosciences). PCR conditions were as follows: 
pre-treatment at 94°C for 3 minutes followed by 25 cycles at 94°C for 30 
seconds, 55°C for 30 seconds, and 72°C for 1 minute. The 925 bp PCR product 
containing the RSV promoter and zeocin gene (RSV-Zeo) was cloned using a 
Topo 2.1 PCR Kit (Thermo) and transformed into Top 10 F’ bacteria (Thermo). 
Clones harboring the PCR product were isolated and the insert recovered by 
digestion with EcoRI followed by gel purification and ligation into pLC118. (The 
plasmid pLC118 was created by cloning the neomycin phosphotransferase gene 
from pSV2neo 200 into a EcoRI-linearized M13mp18. One microliter of the ligation 
mixture was transformed into NEB Turbo electrocompetent bacteria (New 
England Biolabs), and individual clones harboring recombinant M13 molecules 
containing the RSV-Zeo insert were screened by restriction digestion analysis of 
double-stranded virion DNA to determine orientation. Single-stranded virion DNA 
was subsequently recovered from cultures harboring the insert in the two 
different orientations (referred to, respectively, as pLC119 and pLC120) and 
primer extension reactions performed as described above. M13-RSV-Zeo-8oxo 
template or M13-RSV-Zeo-8oxo coding primers (Table 3.1) were used to 
generate double-stranded plasmid substrates in which the 8-oxo-dG residue is 
present on, respectively, the template or coding strands of the RSV-Zeo 
transcriptional unit (Figure S3.1). Transcription of these plasmids following 
transfection into wild-type V79 cells was confirmed via quantitative reverse 
transcriptase PCR using SuperScript VILO (Invitrogen) according to 
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manufacturer’s instructions and primers Zeo F1 and Zeo R1 (Table 3.1) for 
amplification 201.  
 
Purification of single-stranded DNA. Approximately 10 ng of double-stranded 
pLC119 or pLC120 was electroporated into NEB Turbo bacteria according to 
manufacturer instructions and shaken in 1 mL Luria-Bertani broth (LB) for 1 hour 
at 37°C. Either 50 or 100 µL of culture broth was added to 100 µL of an overnight 
culture of non-transfected bacteria and 3 mL of top agar containing 5 mM MgCl2. 
This solution was mixed, poured onto an LB plate, and incubated at 37°C 
overnight. Plaques formed were picked using a Pasteur pipette and incubated in 
1 mL of LB for 3 hours at room temperature followed by 4°C overnight. The next 
day, 100 µL of an overnight culture of NEB Turbo bacteria was diluted into 5 mL 
of LB containing 5 mM MgCl2 and shaken for 2 hours at 37°C. The 5 mL culture 
was then diluted into 45 mL of LB containing 5 mM MgCl2 and divided into 1 mL 
aliquots. Next, 100 µL of diluted plaques were added to each aliquot and shaken 
at 37°C for 5 hours 202. Cultures were then spun at 12K x G in a table-top 
centrifuge for 5 minutes at room temperature 203. The supernatants were 
collected and single-stranded DNA purified using a QiaPrep Spin M13 kit 
(Qiagen).  
 
Transfection. Mammalian cells were plated at 0.5 x 106 cells/well in a 6-well plate 
the night prior to transfection. For a one well transfection, 15 µL (1.2 pmol) of 
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purified, DNA repair substrates prepared as described above was incubated with 
6 µL of lipofectamine (Invitrogen) and 300 µL of serum-free culture media for 5 
minutes at room temperature. (Note that 1 µL of the DNA substrate is reserved 
as non-transfection (i.e. 0 hour time point) controls. This material is diluted in 500 
µL of water and subsequently included in the SSPE-qPCR assay described 
below.) 250 µL of DNA complexes were added to the well and allowed to recover 
for either 1.5, 3, 5, 7, or 8 hours. For multiple well transfections, the above 
conditions were doubled or tripled as needed. Following incubation, cell culture 
media was removed and 1 mL of 0.6% SDS/0.01 M EDTA was added to each 
well for 10-15 minutes at room temperature. Lysed cells were scraped with a 
rubber policeman and transferred to a 1.5 mL centrifuge tube. Sodium chloride 
was added to a final concentration of 1 M, inverted gently 5 times, and incubated 
at 4°C overnight 178. The next day, samples were spun at full speed in a table top 
centrifuge at 4°C for 30 minutes. The supernatant was ethanol precipitated, 
resuspended in 100 µL water and stored at -20°C until SSPE-qPCR. 
 
Strand-specific primer extension-quantitative polymerase chain reaction (SSPE-
qPCR) repair assay. Low molecular weight DNA recovered from transfected cells 
(1 µL) as well as non-transfected DNA samples (0 hour controls) were mixed with 
a PCR primer (1µM) complementary to the damaged strand of the plasmid (M13 
Primer R, Table 1, Figure 3.1) in SYBR green master mix buffer (Invitrogen). 
Following a 10-minute melting step at 90°C, the DNA was melted at 90°C for 15 
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seconds and then reduced to 65°C for 1 minute to permit primer 
annealing/extension. This step was repeated an additional seven times, at which 
point a primer complementary to the undamaged strand of the plasmid (M13 
Primer L, Table 1, Figure 3.1) was added (1µM). Cycle threshold (Ct) values 
were then measured via quantitative real-time PCR on an Applied Biosystems 
StepOnePlus Real Time PCR System using the reaction conditions described 
above. In parallel, a qPCR experiment analogous to that above was performed in 
which the eight rounds of primer extension were omitted. The Ct values from the 
latter experiment were subtracted from that of the former to calculate the delta Ct 
value ΔCt = [Ct] – [Ct primer extension]. Because the presence of an abasic site, 
cholesterol, or DPC lesion blocks primer extension, this delta Ct value can be 
used to calculate the percent of lesion repair using the formula: percent DNA 
repair = (2ΔCt/23) x 100 179,201. The percent repair calculated at each time point 
using this method is then subtracted from the ‘apparent percent repair value’ 
calculated using the 0 hour time point (i.e. non-transfected DNA repair substrate 
sample) to correct for PCR background noise induced by the strand-specific 
primer extension. 
 
Measurement of base excision repair (BER) activity in wild-type and NER-
deficient cell lines. A plasmid containing an 8-oxo-dG modification was 
transfected into Chinese hamster V79 and V-H1 cell lines and low molecular 
weight DNA recovered at 1.5 and 3 hours post-transfection as described above. 
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This material was then treated with 80 pmol of OGG1 enzyme for 30 minutes at 
37°C. Under these conditions, the OGG1 enzyme quantitatively excises any 
unrepaired 8-oxo-dG residues from the plasmid, thereby creating an abasic site 
that blocks primer extension by Taq polymerase. It is thus possible to use the 
strand-specific primer extension-qPCR assay described above to calculate the 
respective levels of BER activity present in wild-type and NER-deficient cell lines. 
 
Measurement of cisplatin-induced DNA-protein crosslinks in Chinese hamster 
cell lines. Wild-type V79 and NER-deficient V-H1 Chinese hamster cells were 
grown to confluence on 10 cm dishes (2 per cell line). One dish each per cell line 
was maintained in serum-free media plus or minus 100 µM cisplatin for one hour 
at 37°C. Cells were then washed twice with PBS and re-suspended at a density 
of 1x107 cells/mL 66. Protein-linked DNA was isolated using 100 µL of cells lysed 
with 0.5 mL 2% SDS, 1mM PMSF, and 20 mM Tris-HCl pH 7.5 and frozen at -
80°C. Cells were then thawed at room temperature, vortexed for 10 seconds, and 
incubated at 65°C for 10 minutes. Next, 0.5 mL of 200 mM KCl in 20 mM Tris-
HCl pH 7.5 was added and the material passed through a 1 mL pipet tip five 
times. Samples were then put on ice for 5 minutes, spun at 3K x G for 5 minutes 
at 4°C, and the pellet resuspended in 1 mL of 100 mM KCl in 20 mM Tris-HCl pH 
7.5 by pipetting 5 times to evenly disperse recovered material. Samples were 
heated to 65°C for 10 minutes, chilled on ice for 5 minutes, and spun at 4°C for 5 
minutes at 3K x G. Resuspension of the pellet in 100 mM KCl in 20 mM Tris-HCl, 
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heating, chilling, and spinning were repeated twice more before resuspending the 
final pellet in 1 mL of 100 mM KCl, 10 mM EDTA, 20 mM Tris-HCl pH 7.5 and 
proteinase K (final concentration 0.2 mg/mL). Samples were incubated at 50°C 
for 3 hours after which 100 µg of bovine serum albumin was added, chilled on 
ice, and spun at 10K x G for 10 minutes at 4°C. The supernatant was collected 
and mixed with 1 mL of freshly prepared 200 ng/mL Hoechst dye 33258 reagent 
(ChemCruz) in 20 mM Tris-HCl pH 7.5, vortexed, and incubated for 30 minutes in 
the dark at room temperature. Total DNA was isolated by lysing 100 µL of cells in 
1 mL of 2M NaCl in 20 mM Tris-HCl pH 7.5 and mixed with the fluorescent agent 
as stated above. Fluorometer measurements of total DNA and protein-linked 
DNA were obtained using a Fluoromax 4 Spectrofluorometer (Horiba) at room 
temperature with 360 excitation and 450 emission filters. Protein-linked DNA 
values were divided by total DNA to obtain percent of protein-crosslinked DNA. 
 
IV. RESULTS 
Taq polymerase extension is blocked by abasic sites.  
 The SSPE-qPCR assay utilized in this study is dependent on the ability of 
the lesions analyzed to permanently stall Taq polymerase extension. To confirm 
this, we performed two parallel primer extension reactions, one using a 40-mer 
oligonucleotide (M13-RSV-Zeo-8oxo (template), see Table 3.1) containing an 8-
oxoguanine residue at position 19, and the other harboring an AP site created by 
OGG1 at this same position (see Methods for details). It has been reported that 
	
68	
Taq polymerase is able to efficiently read-through an 8-oxoguanine residue but is 
blocked by abasic sites 180. We thus anticipated that a primer annealed to the 8-
oxoguanine-containing strand would be extended by Taq polymerase, producing 
a 40-nucleotide product, while a primer annealed to the AP-containing 
oligonucleotide would not be extended to produce a full-length product. The 
densitometry results presented in Figure 3.2 (calculated using ImageJ) confirm 
this prediction, showing the presence of a full-length primer extension product 
when the 8-oxoguanine lesion-containing substrate (8oxo) was extended with 
Taq polymerase in the presence of a complementary primer. In contrast, no 
product was produced when the AP-containing substrate (AP, Figure 3.2) was 
extended with Taq polymerase and a complementary primer. We also observed 
a ~ 21 nucleotide product (data not shown), as would be expected were the Taq 
polymerase stalled at the abasic site. It is noteworthy that creation of an AP site 
using OGG1 can also generate a single-strand break via beta-elimination by 
OGG1 (43). To confirm that Taq polymerase is blocked at abasic sites in the 
absence of single-strand breaks, the above experiment was repeated using an 
oligonucleotide ordered with an abasic modification (abasic, Table 3.1) or no 
lesion (abasic corrected, Table 3.1) in the presence or absence of a 
complementary primer (abasic complement, Table 3.1). These experiments 
confirmed an increase in full-length product during extension of an unmodified 
oligonucleotide but not with an abasic-containing substrate. Additionally, an 18-
nucleotide product corresponding to the site of the abasic lesion was observed 
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during extension of the damaged substrate, indicating halting of the Taq 
polymerase at the lesion, but not in the undamaged oligonucleotide extension 
(Figure S3.2). 
 
Repair of 8-oxo-dG in wild-type and NER-deficient cells.  
While our ultimate objective was to use the SSPE-qPCR assay to 
compare the relative efficiency with which NER proficient and NER-deficient 
clones repaired a DPC-containing plasmid substrate, we first performed two 
series of experiments to confirm: 1. That NER proficient and NER deficient 
clones would repair plasmids harboring a base excision repair substrate with 
equivalent efficiencies, and 2. That a plasmid harboring a lesion known to be 
selectively repaired by the NER pathway would be significantly more efficiently 
repaired in NER proficient cells than in isogenic clones deficient in NER. 
As a first step, we transfected covalently closed circular plasmids harboring a 
site-specific 8-oxo-dG modification (see methods for details of construction and 
purification) into wild-type (V79) and NER-deficient (V-H1) Chinese hamster cell 
lines and, following incubation periods of 1, 1.5 or 3 hours, purified low molecular 
weight DNA from the cells. This material, as well as non-transfected DNA was 
treated with OGG1, was analyzed using SSPE-qPCR, as described in the 
Methods section. As illustrated in Figure 3.3, both wild-type and NER-deficient 
cells showed rapid and efficient repair of 8-oxo-dG lesions indicating that there is 
no appreciable difference in the relative BER activity in V79 and V-H1 clones. (It 
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is critical to note that, as described in the Methods section, the percent repair 
calculated at 1, 1.5 and 3 hours post-transfection was corrected to subtract 
‘apparent repair’ observed in the ‘0 hour’, i.e. no-transfection control.) This result 
is consistent with the interpretation that equivalent amounts of transfected DNA 
gain access to the cellular DNA repair machinery in the two cell lines. We next 
pursued a second series of experiments to test the hypothesis that NER-deficient 
clones would repair a plasmid substrate harboring a known NER substrate with 
reduced efficiently than would their isogenic wild-type counterparts.            
 
Repair of cholesterol adducts in wild-type and NER-deficient cells.  
A plasmid containing a site-specific cholesterol-ribose lesion was prepared 
and purified as described in the methods. It has previously been shown that this 
lesion is subject to NER 182. This substrate was transfected into V79 (NER 
proficient) and V-H1 (NER deficient) cells. Low molecular weight DNA was 
recovered eight-hours post-transfection and subjected to the SSPE-qPCR assay 
to calculate DNA repair activity as described above. As depicted in Figure 3.4, 
the efficiency of repair of the cholesterol-containing plasmids in NER-deficient V-
H1 cells was nearly fifteen-fold lower (4% vs 57%) than that detected in the NER 
proficient V79 cells. To confirm that this difference was indeed due to a defect in 
NER, an identical experiment was performed in human cell lines deficient (XPD) 
or proficient (XPDcorr) in NER. Results from this experiment indicated that repair 
of the cholesterol-containing plasmid in wild-type human cells was six-fold more 
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efficient than that detected in the isogenic NER-deficient clone (63% vs 11%, 
Figure 3.4). (As in the experiment above, repair efficiency values have been 
corrected by subtracting the background seen in the 0 hour, no transfection 
control sample.) These results confirmed the expectation that NER-deficient 
clones would show significantly decreased repair of a cholesterol moiety 
crosslinked to plasmid DNA, and that our SSPE-qPCR assay is capable of 
detecting differences in the repair of adducts processed by the NER pathway. 
 
Crosslinking OGG1 to 8-oxo-dG-containing plasmid DNA substrates.  
As was outlined in the Introduction, proteins become crosslinked to DNA 
via multiple mechanisms. To address specific questions regarding DPC repair on 
plasmid DNA, an enzymatic reaction was chosen to crosslink the repair protein 
OGG1 to a deoxyribosyl residue. This biologically relevant lesion represents the 
main source of endogenous DPCs of apurinic/apyrimidinic (AP) site within 
nucleosome core particles 12. To quantify the crosslinking efficiency of these 
substrates, plasmids containing a site-specific OGG1-DNA crosslink were 
subjected to KCl/SDS precipitation as described in the Methods section. As the 
results in Figure 3.5 illustrate, the 4.4 kb fragment was quantitatively removed 
from the sample in which KCl was added while there is no evident reduction in 
the amount of the 2.8 kb fragment in this sample, compared to the untreated 
control. This result confirms that the crosslinking reaction is highly efficient, with 
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nearly 100% of the plasmid molecules containing a site-specific DNA-protein 
crosslink. 
 
Repair of OGG1 crosslinked to plasmid DNA in Chinese hamster and 
human clones.  
To determine whether the M13 plasmid containing a covalent OGG1 
crosslink is subject to repair, DPC-containing plasmids were transfected into wild-
type V79 Chinese hamster cells. Low molecular weight DNA was recovered 3, 5, 
7 and 8-hours post-transfection as described in Methods. SSPE-qPCR assays on 
this material as well as on a 0 hour, no transfection control, sample was used to 
calculate percent DNA repair as outlined in the Methods section. These results 
revealed essentially linear repair kinetics reaching 28% repair at the final time 
point (Figure 3.6, left panel), indicating that V79 cells are capable of repairing 
OGG1 crosslinked to a non-replicating plasmid DNA molecule. We performed 
similar experiments in a second Chinese hamster-derived cell line (CHO-K1), as 
well as in two human wild-type cell lines. In each instance, these clones were 
capable of repairing the plasmid DPC lesion (Figure 3.6, right panel). 
Interestingly, DPC repair efficiency in each of the hamster clones was in the 
range of ~20-25%, whereas the corresponding repair efficiency in two human cell 
lines derived from unrelated donors was significantly greater (>70%). While there 
was no significant difference in the repair levels between species, the level of 
DPC repair detected in human cells was significantly greater than that detected 
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in the Chinese hamster-derived clones. Interestingly, despite this species-specific 
difference in DPC repair activity there was no significant difference in the 
efficiency with which human and hamster cells repaired the cholesterol lesion 
(63% vs 57%, Figure 3.4). 
 
Reduced DPC repair in Chinese hamster and human clones deficient in 
NER.  
To test the hypothesis that DPCs are repaired by the NER machinery, we 
transfected the DPC-containing plasmid into isogenic NER-deficient and NER-
proficient Chinese hamster and human clones, and used the methodology  
outlined above to quantitatively measure cellular repair activity. Consistent with 
our prediction, DPC repair efficiency was dramatically lower in NER-deficient 
cells compared to their isogenic NER-proficient counterparts (Table 3.2). 
Chinese hamster V-H1 cells (XPD deficient) repaired the DPC nine-fold less 
efficiently than did their isogenic, wild-type counterpart V79 (3% vs 27%). 
Similarly, XPD deficient human cells repaired the DPC nearly four-fold less 
efficiently than did their gene-corrected counterpart (20% vs 73%). We extended 
this analysis to look at the effect of inactivation of another NER gene. As Table 
3.2 illustrates, inactivation of the human XPA gene was associated with a five-
fold reduction in DPC repair efficiency (16% vs 78%). In all instances the 
differences in DPC repair activity observed between NER-deficient and NER-
proficient clones were statistically significant. These results indicate that in 
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mammalian cells, the NER pathway is capable of rapidly and efficiently repairing 
plasmid DPC substrates.  
 
Table 3.2. OGG1-DNA crosslink repair in NER-deficient cells. *Values depict 






Transcription-coupled repair of OGG1 crosslinked to a plasmid in Chinese 
hamster cells.  
The NER pathway is comprised of two distinct sub-pathways, respectively 
referred to as the transcription-coupled (TC) and global genome (GG) pathways 
204. The DPC substrate studied in the experiments presented above was 
localized within a portion of the plasmid that was transcriptionally silent. 
Consequently, we conclude that the repair events we detected were catalyzed by 
the global genome NER pathway. To determine whether TC-NER is also capable 
of repairing DPCs, molecular cloning was employed to generate plasmids 
harboring an 8-oxo-dG-residue localized within a minigene encoding the bacterial 
zeocin-resistance gene driven by the RSV promoter. Because of the way these 
clones (pLC119/pLC120) were generated, the 8-oxo-dG residues were present, 
Percent Repair* 
(mutated)   
Percent Repair* 
(control)  
Fold Reduction  
(vs control) 
V-H1 (3 ± 1) V79 (27 ± 2) 9 
XPD (20 ± 7) XPD Corr (73 ± 5) 3.7 
XPA (16 ± 5) XPA Corr (78 ± 10) 4.9 
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respectively, on the coding, or template strands of the DNA (Details of the 
creation of these clones, as well as how the activity of the RSV/zeocin 
transcription unit in Chinese hamster cells is described in the Methods section). 
We subsequently crosslinked recombinant OGG1 protein to the 8-oxo-dG 
residues in the pLC119 and pLC120 plasmids via the cyanoborohydride-trapping 
technique outlined above to generate plasmid substrates harboring a DPC with 
either the template or coding strand of the RSV/zeocin transcriptional unit. To 
confirm that the crosslinking efficiency of OGG1 was similar in both plasmids, 
KCl/SDS precipitation was performed on DPCs crosslinked to the template or 
coding strand. The soluble material remaining was resolved by agarose gel 
electrophoresis (see Methods for details), and scanning densitometry performed 
using ImageJ software. This analysis revealed that the crosslinking efficiency on 
the two clones was 94% and 95%, respectively (data not shown). The two 
plasmid DPC substrates were subsequently transfected into wild-type (V79) and 
NER-deficient (V-H1) Chinese hamster cell lines and their respective repair 
efficiencies determined using the strategy outlined above. Based on results from 
experiments investigating the repair of actively transcribing loci within 
mammalian cells exposed to UV radiation, we predicted that DPC lesions present 
on the template strand would be repaired more efficiently that would lesions 
present on the coding strand 205. The results depicted in Figure 3.7 are 
consistent with this expectation, showing that a DPC present on the template 
strand was repaired approximately 2.5-fold more efficiently than was an identical 
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DPC lesion present on the coding strand. The data further illustrate that for both 
lesions, repair occurs significantly less efficiently in the NER-deficient V-H1 
background than in its wild-type counterpart. 
 
A 4 kDa DNA-peptide crosslink is repaired more efficiency than a 38 kDa 
DPC.  
Results from our lab and others confirm that several agents are able to 
crosslink proteins of dramatically different sizes to DNA, both in vitro as well as in 
intact cells 4,16,206. It has been suggested that the size of the protein crosslink 
may influence the pathway through which a DPC lesion is repaired 61. We thus 
sought to examine whether a substantially smaller DPC substrate would also be 
subject to NER-mediated removal. To achieve this objective, OGG1-crosslinked 
plasmid DNA substrates were exhaustively digested with trypsin (see Methods) 
to generate a substrate in which a 39-amino acid residual (~4.9 kDa) peptide 
fragment remained attached to the DNA (Figure S3.3). This peptide-DNA 
crosslink substrate was transfected into Chinese hamster V79 and V-H1 cells 
and repair efficiency analyzed at three and eight hours post-transfection using 
the SSPE-qPCR assay, as outlined above. The results in Figure 3.8 indicate that 
repair of this DNA peptide substrate was significantly more efficient in the NER-
proficient V79 cells than in their isogenic NER-deficient V-H1 counterparts. 
Interestingly, the DNA peptide (39 amino acid residue) crosslink was repaired 
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approximately twice as efficiently as was the full length OGG1 DNA-protein (345 
amino acid residue) crosslink (43% Figure 3.8 vs 27% Figure 3.6).  
 
Repair of cisplatin-induced chromosomal DPCs in wild-type and NER-
deficient Chinese hamster cells.  
The results presented above convincingly demonstrate that both the 
global genome and transcription-coupled NER pathways are able to efficiently 
repair a DPC comprised of the OGG1 protein (or a proteolytic fragment derived 
therefrom) covalently trapped onto a deoxyribosyl residue of a plasmid DNA 
molecule. However, it is conceivable that similar substrates crosslinked to 
genomic DNA may be subject to different DNA repair pathways, or that the 
nature of the chemical bond linking protein to DNA can influence the 
mechanism(s) through which DPCs are repaired. To confirm that results obtained 
using the SSPE-qPCR assay generally reflect the ability of the NER machinery to 
repair DPCs present on chromosomal DNA, we quantitated the level of 
accumulated DNA-protein crosslinks present in wild-type and NER-deficient cells 
following exposure to cisplatin. We hypothesized that if NER plays a significant 
role in repair of chromosomal cisplatin-induced lesions, levels of DPCs present 
following a one-hour exposure to 100 µM cisplatin would be elevated in V-H1 
cells, compared to V79 cells. The results in Figure 3.9 illustrate an approximate 
3.6-fold higher level of DPCs in cisplatin-treated V-H1 cells compared to their 
wild-type, isogenic counterpart, consistent with the interpretation that the NER 
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pathway plays a significant role in the repair of drug-induced chromosomal 
DPCs.  
          
V. DISCUSSION 
In this report, we describe the development of a DNA repair assay we 
named strand-specific primer extension-quantitative PCR (SSPE-qPCR) and 
illustrate its utility in studying the repair of lesioned plasmids transfected into wild-
type and NER-deficient human and Chinese hamster-derived cell lines. The 
versatility of this assay permits one to generate multiple distinct DNA repair 
substrates and subsequently measure the respective efficiencies with which they 
are repaired in different genetic backgrounds. In this way, we were able to show 
that both human and Chinese hamster-derived clones are able to efficiently 
repair episomal plasmids harboring a DPC, and that in both species this process 
was primarily dependent on the NER machinery. We presented evidence that 
both the GG and TC sub-pathways of NER can contribute to mammalian DPC 
repair. Our results also indicated that a DNA-crosslinked 39 amino acid 
polypeptide was repaired significantly more efficiently than was a 345 amino acid 
protein crosslink. While in this instance, our primary focus was on DNA protein 
crosslink repair, our results illustrate that with appropriate modifications this 
assay would be useful in the study of any number of DNA lesions. 
This study was undertaken in an attempt to resolve a controversy in the 
literature regarding the role of nucleotide excision repair in the removal of DNA-
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protein crosslinks. Baker et al. (31) detected higher levels of host cell reactivation 
activity of a DPC containing plasmid transfected into NER-proficient cells 
compared to that detected in a NER-deficient clone. This group presented 
additional information leading them to conclude that larger protein crosslinks 
were proteolytically degraded to smaller peptide crosslink lesions that were 
subsequently repaired in an NER-dependent manner. In contrast, Nakano et al. 
(30) published results supporting a model in which the mammalian NER pathway 
was only capable of repairing DPCs smaller than approximately 10 kDa. In an 
effort to resolve this apparent paradox, we developed the SSPE-qPCR assay 
and used it to compare the relative efficiency with which NER-deficient and NER-
proficient isogenic cell line pairs repaired a synthetic DPC substrate. Critically, as 
part of our experimental design, we also compared the relative efficiency with 
which these same cell line pairs repaired plasmid substrate harboring an 8-oxo-
dG residue or a site-specific cholesterol moiety. While the former lesion is 
repaired by the base excision repair machinery, the latter lesion is known to be 
subject to NER repair. We were thus able to use these latter repair substrates as, 
in effect, negative and positive controls for the SSPE-qPCR assay. Were the 
assay faithfully monitoring cellular DNA repair function, there should be no 
difference in 8-oxo-dG repair activity between the NER-deficient and NER-
proficient clones, however, these latter cells should display significantly greater 
repair efficiency directed towards the cholesterol substrate. Results presented 
above confirmed these predictions. Thus, our subsequent finding that repair of a 
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DPC substrate was significantly reduced in the NER-deficient V-H1 cells, 
compared to their wild-type isogenic counterpart V79 is most consistent with the 
interpretation that the primary mechanism of repair of this substrate is NER. 
While our assay cannot definitively rule out the possibility that differential kinetics 
of plasmid nuclear uptake or transfection efficiency influence DPC repair 
efficiency, these potential explanations are inconsistent with our finding that there 
was no statistically significant difference in the cycle threshold values obtained 
from experiments in which plasmid DNA harboring 8oxoG or DPC lesions were 
transfected into WT and NER-deficient cell lines.  Additional support for the 
interpretation that plasmid DPC repair activity in mammalian cells is primarily due 
to NER was obtained when we showed that human clones deficient in the XPA or 
XPD genes also showed greatly diminished efficiency of repair of the DPC 
substrate, compared to their isogenic wild-type counterparts. 
Another advantage to using the SSPE-qPCR assay to study the repair of 
DNA substrates, is that parameters such as sequence context can be easily 
manipulated to assess their influence on repair. We demonstrated this by 
crosslinking a DPC to either the template or coding region of a transcriptional unit 
and measuring differences in repair efficiency using the SSPE-qPCR assay. 
Results from this experiment revealed that DPCs crosslinked to the template 
strand were repaired significantly higher than those attached to the coding strand 
and that in both cases, repair was significantly decreased in NER-deficient 
clones. Based on these observations we conclude that the TC-NER pathway is 
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able to repair DPCs. It is notable that the repair efficiency of the template strand-
containing DPC in this sequence context (32%) was not appreciably different 
from the ~28% repair efficiency observed for a substrate present in a locus that 
does not support transcription (see Figures 3.6 and 3.7). Thus, it appears that 
additional factors besides transcription can influence DPC repair efficiency. For 
example, it is conceivable that additional factors, such as sequence context, 
%GC composition, etc., could potentially influence the efficiency of DPC repair. 
In addition to investigating these possibilities, it will be of interest to examine the 
effect on DPC repair of replication by generating a DPC on a plasmid containing 
an origin of replication. 
Although our repair data refute the hypothesis that NER is incapable of 
repairing lesions larger than 10 kDa, we wanted to further investigate whether a 
DNA-peptide crosslink (~4 kDa) would be more efficiently repaired than a DPC 
(38 kDa) using the SSPE-qPCR assay. Results presented above confirmed that 
the smaller, DNA-peptide crosslink was repaired twice as efficiently as the OGG1 
crosslink in wild-type cells and that repair of either of these lesions was also 
dependent on the NER pathway. This data is consistent with the hypothesis that 
repair of DPC lesions requires one or more processing steps, and that a larger 
protein substrate requires more processing than does a smaller, peptide-
crosslink substrate. Several publications have shown that the yeast WSS1 and 
its human homolog Spartan are DNA-dependent proteases that play critical roles 
in DPC repair 6,93,94. Currently Spartan’s role in DNA damage tolerance and DPC 
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repair is not fully understood but it’s thought to be replication-coupled 96,98,207. It 
has been shown that Spartan-deficient worms are hypersensitive to DPC-
inducing agents, and that patients with Ruijs-Aalfs syndrome possessing 
germline mutations in the Spartan gene develop early onset hepatocellular 
carcinoma, as do mice hemizygous for the Spartan gene 97,98,208. It is conceivable 
that this cancer predisposition phenotype reflects a defect in repair of 
endogenously produced DPCs. Although our data are consistent with the 
hypothesis that non-replicating plasmids are also subject to proteolytic 
processing, additional experiments using the SSPE-qPCR assay will be required 
to rigorously test this. It will also be important to determine whether, as others 
have proposed (Baker et al.), the proteasome is capable of processing proteins 
crosslinked to DNA. 
It is notable that results generated using the SSPE-qPCR assay 
uncovered a species-specific difference in DPC repair efficiency. While the 
overall repair efficiency of crosslinked OGG1 in two human cell lines obtained 
from unrelated donors exceeded 70%, repair efficiency of this substrate in two 
different Chinese hamster-derived clones was significantly lower (~20%). As the 
data in Figure 3.4 illustrates, there is essentially no difference in the efficiency 
with which the cholesterol lesion is repaired in human versus Chinese hamster-
derived cells. Thus, the species-specific difference in DPC repair efficiency is not 
due, per se, to reduced levels of NER activity in hamster cells. Based on data 
implicating the involvement of proteolysis in DPC repair, it is tempting to 
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speculate that human cells possess a more active protease to generate smaller 
adducts that can be more easily excised by the NER machinery. Currently, 
experiments are underway to employ the SSPE-qPCR assay to determine the 
precise cause of this DPC repair deficit in Chinese hamster clones and determine 
whether it reflects a trend of reduced DPC repair activity in the cells of other 
short-lived mammals.  
Finally, we tested the hypothesis that chromosomal DPC lesions formed 
following cisplatin treatment are subject to repair via the NER machinery. We 
determined that NER-deficient cells harbored significantly higher levels of 
cisplatin-induced DPCs than did isogenic wild-type cells immediately following a 
one hour incubation with 100µM cisplatin. We are currently using the SSPE-
qPCR assay to assess the role of additional repair pathways, such as 
homologous recombination as a potential mechanism through which mammalian 
cells repair DPCs.  
  
VI. CONCLUSIONS 
The SSPE-qPCR assay detailed above demonstrates a new way to 
quantitatively assess the repair mechanisms involved in DPC repair on plasmid 
substrates. This method is easy, sensitive, and capable of directly quantifying 
DPC repair at time points as early as 2 hours post-transfection. Using this assay, 
parameters such as DPC size, chemical crosslink, and DNA sequence context 
can be independently assessed to gain insight into the efficiency with which the 
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plasmid DPC is repaired. Initial studies in our lab using the SSPE-qPCR assay 
have demonstrated that DPC lesions on transcribing and non-transcribing 
plasmids are repaired by a mechanism that is dependent on the nucleotide 
excision repair pathway and that DNA-peptide crosslinks are repaired at a higher 





Figure 3.1: Quantification of damaged plasmid via strand-specific primer 
extension/qPCR (SSPE-qPCR). Repair of damaged plasmids is quantified using 
SSPE-qPCR: (1) Plasmid DNA is denatured, (2) a primer extension reaction is 
performed using primer R, (3) the denaturation/primer extension step is repeated 
and additional 7 cycles. After 8 cycles, primer L is added and Ct values 
determined using qPCR. The presence of an abasic site, cholesterol, or DPC (A) 
will cause Taq polymerase to stall, resulting in no full-length product strands. In 
contrast, when repair has occurred (B), Taq polymerase will produce full-length 



















Figure 3.2: An AP site blocks Taq-mediated primer extension. Taq 
polymerase extension reactions were performed as described in the text on 40-
mer oligonucleotides containing either an 8-oxo dG residue (8oxo) or an AP site 
(AP), see methods section for details, in the absence (-) or presence (+) of 
complementary primer Z (15-mer, see methods). The products were resolved by 
electrophoresis, stained with ethidium bromide and subject to scanning 
densitometry. The relative amount of full-length product (40 nt) was quantitated 






Figure 3.3: 8-oxo-dG repair efficiency is similar in wild-type and NER-
deficient Chinese hamster clones. An oligonucleotide containing an 8-oxo-dG 
modification (O, in red) is annealed to single-stranded M13 and a primer 
extension reaction performed as described in the Methods. Covalently closed 
circular double-stranded DNA is gel-purified, and transfected into wild-type V79 
(blue) and NER-deficient V-H1 (red) Chinese hamster cells via lipofection. Low 
molecular weight DNA was recovered 1, 1.5 and 3-hours post-transfection and 
treated with OGG1 to convert unrepaired 8-oxo-dG residues to abasic sites. DNA 
repair assays were then performed as described in the legend to Figure 1. 







Figure 3.4: Cholesterol-DNA adducts are repaired with reduced efficiency in 
NER-deficient cells. Plasmid DNA containing a cholesterol adduct was 
transfected into Chinese hamster (blue) and human (orange) cells lines proficient 
(dark bars) or deficient (light bars) in NER via lipofection and low molecular 
weight DNA recovered after 8 hours. DNA repair assays were performed as 










Figure 3.5. Creation of an OGG1-plasmid DNA crosslink substrate. (A) 
Plasmid DNA containing an 8-oxo-dG residue (O, in red) was reacted with OGG1 
in the presence of sodium cyanoborohydride to create a covalent bond between 
lysine residue 249 and a deoxyribosyl moiety on the plasmid (see Methods for 
details, chemical structure depicted in inset). (B) This product was cut with 
restriction enzymes to generate two fragments: a 2800 bp protein-free DNA 
fragment and a 4400bp fragment crosslinked to OGG1. (C) The restriction 
digested material was resolved by agarose gel electrophoresis prior to (lane 2) or 
following (lane 3) precipitation in the presence of K-SDS (see Methods), and 
stained with ethidium bromide. The arrow illustrates the selective loss of the 
OGG1-crosslinked DNA fragment following K-SDS precipitation. Lane 1; 




Figure 3.6: OGG1-DNA crosslink repair in wild-type cells. Left: Plasmid 
crosslinked to OGG1 was transfected into V79 cells via lipofection, low 
molecular weight DNA recovered 3, 5, 7, and 8 hours post-transfection, 
and repair assays performed as described above. The graph depicts mean 
percent repair, ± SEM, N=3. Right: Plasmid DNA containing an OGG1 
crosslink was transfected into: Chinese hamster ovary (CHO-K1, green), 
Chinese hamster lung fibroblast (V79, blue), and human (XPDcorr, orange 
and XPAcorr, purple) cells, low molecular weight DNA recovered 8 hours 
post-transfection and repair assays performed as described above. Values 







Figure 3.7: OGG1-DNA crosslinks are repaired more efficiently when 
present on a template strand than when present on a coding strand. 
Plasmid pLC119/pLC120 DNA substrates containing an OGG1 crosslink 
present on the template strand (left), or coding strand (right) of a 
transcriptional unit (construction described in Methods) were transfected 
into wild-type (V79, dark bars) and NER-deficient (V-H1, light bars) cells, 
and repair assays performed as described above. The graph depicts 








Figure 3.8: A DNA-peptide crosslink is 
repaired with reduced efficiency in 
NER-deficient Chinese hamster cells.  
Plasmid DNA containing a DNA-peptide 
crosslink (prepared as described in the 
Methods) was transfected into wild-type 
(V79, dark bars) or NER deficient (V-H1, light bars) Chinese hamster cells via 
lipofection, low molecular weight DNA recovered at 3 and 8 hours post-
transfection, and repair assays performed as described above. The graph depicts 
mean percent repair, ± SEM, N=4, *P < 0.05. 
	
Figure 3.9: Cisplatin-induced DNA-protein 
crosslinks accumulate at elevated levels in NER-
deficient Chinese hamster cells. Wild type (V79, 
dark bar) and NER-deficient (V-H1, light bar) Chinese 
hamster cells were exposed to 100 µM cisplatin for 
one hour in serum-free media, and levels of 
chromosomal DPCs determined. The graph depicts 
mean percent of protein-crosslinked DNA (calculated 




Supplemental Figure 3.1: Schematic of plasmid pLC119. The upper panel 
depicts plasmid pLC119, which was created by cloning a minigene comprised 
of the RSV promoter (blue box) and the coding region of the zeocin gene 
(black box) into pLC118 (see Methods for details). Black arrows indicate the 
EcoRI cloning sites and the red triangle indicates the location of the 8-oxo-
guanine on the coding (pLC120) or template (pLC119) strands of the plasmid. 
The lower panel provides the sequence of attachment sites on the coding or 
template strands, with the blue arrow indicating the direction of transcription, 
the ATG site highlighted in bold, and the respective 8-oxo-guanine residues 








Supplemental Figure 3.2: An abasic site blocks Taq-mediated primer 
extension. Taq polymerase extension reactions were performed on 37-mer 
oligonucleotides containing either a deoxyguanine residue (dG) or an abasic 
site (abasic) annealed to a 12-mer complementary oligonucleotide. The 
primer extension reaction products were resolved by electrophoresis, stained 
with ethidium bromide and subject to scanning densitometry. The relative 
amount of full-length product (blue bars) and 18-mer product (orange bar, 
anticipated length of a primer extension terminated at the abasic site) was 






Supplemental Figure 3.3: Trypsin digestion of a DNA-OGG1 crosslink. 
OGG1 was crosslinked to duplex oligonucleotide, incubated overnight with 
trypsin, followed by a 30 minute treatment with DNASE 1, and resolved on a 
16% Tris-Tricine gel, and stained with simply blue (see methods). Arrow 
refers to the 39mer peptide (~4.9 kDa) proteolysis product, corresponding to 
the OGG1 tryptic fragment that was crosslinked to DNA. Lanes: (M) Molecular 
weight markers (kDa) (D) OGG1 digest. Bracket indicates presence of 
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DNA-protein crosslinks (DPCs) are toxic lesions formed on nuclear and 
mitochondrial DNA. However, details of their repair mechanisms have yet to be 
fully elucidated. The work described below presents direct evidence for the role 
of homologous recombination (HR) in the repair of DPC-containing plasmids 
transfected into the nucleus and mitochondria of mammalian cells. Using a new 
strand-specific primer extension-qPCR assay, we have made the following 
observations. 1.) In the absence of the nucleotide excision repair pathway (NER), 
DPC-containing plasmids were repaired in the nucleus and mitochondria via HR. 
When compared to repair in the absence of a donor, DPC repair in the presence 
of a homologous donor increased two-fold in NER-deficient hamster cells (22% 
vs 11%) and five-fold in NER-deficient human cells (73% vs 14%). DPC-
containing plasmids were not repaired in mitochondria unless a homologous 
donor plasmid was co-electroporated with the damaged substrate. This repair 
exhibited linear kinetics over time and increased two-fold when the DPC 
substrate harbored an adjacent DNA double-strand break. 2.) The RAD51 protein 
but not the RAD51D paralog is required for HR repair of DPC-containing 
plasmids in the nucleus and mitochondria. Pre-treatment of human cells with the 
RAD51 inhibitor B02 showed significantly decreased repair of DPC-containing 
plasmids in the nucleus (15% vs 59%) and mitochondria (0% vs 9%) while 
RAD51D knockout cells showed no difference in repair compared to wild-type. 3.) 
HR is not involved in the repair of smaller DNA-peptide crosslinks in the nucleus. 
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Inhibition of the RAD51 protein in human cells had no effect on the repair of a 4 
kDa peptide crosslinked to plasmid DNA (28% vs 33%). 4.) The mitochondrial 
genome can be used as a donor for repairing homologous DPC-containing 
plasmids. DPCs crosslinked to a plasmid containing a 475bp insert homologous 
to the human mitochondrial genome were repaired when electroporated into 
mitochondria without a donor plasmid. Overall, this data extends previous 
observations of HR and NER in the repair of DPCs in the nucleus and provides 
new insight into DPC repair mechanisms in mammalian mitochondria.  
 
II. INTRODUCTION 
As explained in Chapter 1, DNA-protein crosslinks (DPCs) are toxic 
lesions formed by a variety of DNA-damaging agents1,15,24. These lesions are 
challenging to study due to their heterogeneous nature and induction with other 
types of DNA damage3,8. Several methods have been used to study their repair, 
including a new strand-specific primer extensions-quantitative polymerase chain 
reaction (SSPE-qPCR) assay described in Chapter 290. Initial results using this 
SSPE-qPCR assay, confirmed a role for both the global genomic and 
transcription-coupled nucleotide excision repair (NER) pathway in the repair of 
DPC-containing plasmids transfected into mammalian cells91. However, other 
DNA repair pathways, such as homologous recombination (HR) and proteolysis, 
have been suggested to play a role in DPC repair61,92,93,101. To assess the role of 
HR, we co-transfected DPC-containing plasmids with an undamaged, 
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homologous donor into mammalian cells and calculated their repair using SSPE-
qPCR. We also used this assay to measure differences in DPC repair in cells 
deficient in the protease Spartan and cells treated with the proteasome inhibitor 
lactacystin. 
Mitochondrial DNA is also exposed to DNA-damaging agents and forms 
DPCs209. However, it is unknown how DPCs are repaired in the mitochondria. To 
gain insight into the mechanisms involved in mitochondrial DPC repair, we 
electroporated DPC-containing plasmids with and without a homologous donor 
into purified mitochondria and quantified repair using the SSPE-qPCR assay. 
Overall, results from these experiments provide strong evidence for the role of 
homologous recombination in the repair of DPCs in the nucleus and 
mitochondria.  
 
III. MATERIALS AND METHODS 
Materials 
Chemicals and enzymes. Chemicals were purchased from Sigma Chemical (St. 
Louis, MO) unless otherwise indicated. Materials and enzymes needed for 
creation of 8-oxo-guanine and OGG1-containing plasmids and the SSPE-qPCR 






Table 4.1. Oligodeoxynucleotides (ODNs) used is this study (5’à3’). 


















Cell lines. The human fibrosarcoma cell line HT1080 (CCL-121) were purchased 
from the American Type Culture Collection and human embryonic kidney cells 
expressing the large-T antigen (HEK293T) were a kind gift from Dr. Ashis Basu 
(University of Connecticut). Immortalized human dermal fibroblasts from 
xeroderma pigmentosum patients with inactivating mutations in the NER XPD 
gene (GM08207) were obtained from the Coriell institute. Human cells were 
cultured in Dulbecco’s modified Eagle’s media (Life Technologies, Grand Island, 
NY) supplemented with 9% fetal bovine serum. Chinese hamster AA8 knockout 
51D1 cells were a kind gift from Professor Claudia Wiese (Colorado State 
University) in which the RAD51D gene was knocked out using a gene-targeting 
vector210. RAD51D is a paralog of RAD51 which contributes to the homologous 
recombination pathway in vertebrates211. These cells were cultured in alpha 
minimal essential medium (Life Technologies, Grand Island, NY). Chinese 
hamster lung fibroblast cell line V79 (GM16136) and V-H1 (GM16141) were 
obtained from the Coriell Institute for Medical Research (Camden, NJ) and 
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cultured in Ham’s F-12 modified essential Eagle’s media (Life Technologies, 
Grand Island, NY) supplemented with 9% fetal bovine serum (Atlanta Biologics, 
Atlanta, GA). V79 are wild-type cells from which the V-H1 clones were derived 
following an ethylnitrosourea-induced mutagenesis screen198. V-H1 cells belong 
to nucleotide excision repair complementation group 2 and lack a functional XPD 
gene. All cells were maintained in a humidified atmosphere of 5% carbon dioxide, 
95% air, at 37°C.  
 
Methods  
Creation of DPC-containing substrates. DPC-containing oligonucleotides 
crosslinked via 7-deaza-guanine and 5-formyl-cytosine were created by Shaofei 
Ji (University of Minnesota) using reductive amination and oxime ligation181,212. 
These substrates were then annealed to single-stranded M13, extended, and 
purified as previously described91. All other damaged substrates were created 
according to Chesner and Campbell, DNA Repair, 2018. 
 
Transfection of DPC-containing plasmids into cultured cells. DPC-containing 
plasmids were transfected into mammalian cells lines, recovered, and subjected 
to SSPE-qPCR as previously described91. Experiments involving the 
cotransfection of a homologous donor used 300 ng (3µL) of M13mp18 (New 




Cell treatment with the proteasome inhibitor lactacystin. Transfection of plasmids 
containing an 8-oxo-guanine residue, cholesterol lesion, or OGG1 crosslink were 
performed as previously described following treatment with the proteasome 
inhibitor lactacystin (10µM) for 3 hours at 37°C91,194. 
 
Treatment with B02 inhibitor. For experiments assessing DPC repair in the 
nucleus, prior to transfection, XPD cells were treated with 5µM of the RAD51 
inhibitor B02 (Sigma) for 1 hour at 37°C213. For experiments assessing DPC 
repair in mitochondria, HEK293T cells were treated with 5µM of the RAD51 
inhibitor B02 (Sigma) for 1 hour prior to mitochondria purification.  
 
Purification of nuclei. Note: cells and reagents were kept cold or on ice at all 
times during purification. Eight 15cm dishes of wild-type Chinese hamster 
fibroblasts (V79) were grown to confluency, scraped with a rubber policeman into 
a 15mL conical tube, and spun down in a table-top centrifuge for 5 minutes at 
1000 X G. Cells were washed twice with 5mL of 1X PBS and resuspended in 
2mL of Buffer A (10mM Tris-HCl pH 7.4, 10mM MgCl2, 10mM KCl, and 1mM 
DTT). Resuspended cells were then incubated on ice for 10-15 minutes and 
broken with 20 strokes of a dounce homogenizer and ‘loose’ pestle214. Broken 
cells were spun in a table-top microcentrifuge at 1150 x G for 8 minutes at 4°C 
and washed with 0.5mL of NIB-250 Buffer (15mM Tris-HCl pH 7.5, 60mM KCl, 
15mM NaCl, 5mM MgCl2, 1mM CaCl2, 250mM sucrose, and 1mM DTT)215. The 
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resuspended pellet was then spun using the same conditions described above. 
The final nuclei pellet was resuspended in 800µL NIB-250 Buffer, divided in half, 
and mixed with 100ng of 8-oxo-guanine or DPC-containing plasmid. Samples 
were then transferred to a chilled, 4mm gap cuvette (Fisher Scientific, Waltham, 
MA) and electroporated using a ECM 630 Electro Cell Manipulator (BTX, 
Molliston, MA) at a field strength of 300V/cm, resistance of 25Ω, and 950µF 
capacitance. Following electroporation, samples were transferred to a 
microcentrifuge tube, spun down using the same conditions as above, and 
resuspended in 400µL Incubation Buffer (40mM Tris-HCl pH 7.4, 25mM NaCl, 
5mM MgCl2, 10% glycerol, 1mM pyruvate, 1mM ATP (Teknova), 1 mg/mL BSA 
(New England Biolabs), and 10µM dNTPs (Thermo Scientific))216. Nuclei were 
incubated in a 37°C water bath for 2 hours and lysed with 0.6% SDS/0.01M 
EDTA (final concentration) at room temperature for 12 minutes. Chromosomal 
DNA was then precipitated by adding NaCl to a 1M final concentration and 
incubated at 4°C overnight. The next day, samples were spun in a table-top 
microcentrifuge at 21130 X G for 30 minutes at 4°C. The supernatant was 
ethanol precipitated overnight at -20°C and resuspended in 50µL of water66. One 
microliter of this sample was used to calculate percent repair using SSPE-qPCR 
as previously described90.  
 
Mitochondria purification. Note: cells and reagents were kept cold or on ice at all 
times during purification. Hamster V79 or human HEK293T cells were grown to 
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confluency in four 15cm dishes and mitochondria purified as described in Yoon 
and Koob et al., NAR, 2003216. Cells were scraped into conical tubes and 
washed twice with 5mL of buffer containing 1mM Tris-HCl pH 7.0, 0.13M NaCl, 
5mM KCl, and 7.5mM MgCl2 in a table-top centrifuge at 1000 X G for 5 minutes 
at room temperature. The cell pellet was resuspended in half the cell volume with 
0.1X incubation buffer (IB buffer) consisting of 4mM Tris-HCl pH 7.4, 2.5mM 
NaCl, and 0.5mM MgCl2 and broken with 10 strokes of a dounce homogenizer. 
One-ninth the volume of the original cell pellet was then added of 10X IB buffer 
(400mM Tris-HCl pH 7.4, 250mM NaCl, and 50mM MgCl2) to reach a final 
concentration of roughly 1X. This sample was then transferred to a 
microcentrifuge tube and spun in a table-top microcentrifuge at 376 x G for 5 
minutes at 4°C. The supernatant was then transferred to a new tube and spun 
again to completely rid the sample of any unbroken cells and nuclei. To purify 
mitochondria, the supernatant was spun in a table-top microcentrifuge at 21130 
X G for 10 minutes at 4°C. The mitochondria were then washed with 0.5mL of 1X 
IB buffer (40mM Tris-HCl pH 7.4, 25mM NaCl, and 5mM MgCl2) and spun again 
using the same conditions stated above. Purified mitochondria were then 
resuspended in the respective buffer for the cytochrome c oxidase assay, 
bicinchoninic acid assay, or electroporation assay listed below. 
 
Cytochrome c Oxidase Assay. One-hundred and forty micrograms of purified 
mitochondria (described above) from HEK293T cells was resuspended in 200µL 
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of 1X IB buffer (40mM Tris-HCl pH 7.4, 25mM NaCl, and 5mM MgCl2) and split 
into two samples of 100µL each. These samples were then spun in a table-top 
microcentrifuge at 21130 X G for 10 minutes at 4°C. One sample was 
resuspended in 100µL of a lysis buffer containing 10mM Tris-HCl pH 7.4, 10mM 
MgCl2, and 10mM KCl and the other in 100µL of 1X IB buffer. Both samples were 
incubated on ice for 1 hour. After the incubation period, 40µL of each sample was 
set aside to use for a bicinchoninic acid assay (see below). Fifty microliters of the 
remaining sample were resuspended in lysis buffer and used to confirm 
cytochrome c oxidase activity according the manufacturer’s protocol 
(CYTOCOX1, Sigma-Aldrich). Thirty-three microliters of the remaining sample 
resuspended in 1X IB buffer was used to measure the outer membrane integrity 
of the mitochondria (CYTOCOX1, Sigma-Aldrich). Results from these 
experiments showed that 72% of purified mitochondria had intact outer 
membranes (N=3). 
 
Bicinchoninic acid assay (BCA). Following resuspension in lysis buffer (see 
above), 40µL of the sample was diluted with another 40µL of lysis buffer. In 
contrast, samples saved in 1X IB buffer were spun in a table-top microcentrifuge 
at 21130 X G for 10 minutes at 4°C and resuspended in 80µL of water. Diluted 
albumin (BSA) standards were then prepared in lysis buffer or water according to 
the manufacturer’s protocol (23225, Thermo Scientific) and 25µL of each diluted 
standard was added to a 96-well plate (3595, Costar) along with 25µL of each 
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sample in either lysis solution or water (loaded in triplicate). The protein 
concentration was determined according to the manufacturer’s protocol (23225, 
Thermo Scientific).  
 
Electroporation of purified mitochondria. The final mitochondria pellet was 
resuspended in 50µL 0.33M sucrose/10% glycerol and mixed with 100ng of an 8-
oxo-guanine or DPC-containing plasmid (15µL) (see Chesner and Campbell, 
DNA Repair, 2018 for details). For co-electroporation experiments, 100ng of 
damaged DNA was mixed with 25ng (1µL) of undamaged M13mp18 (New 
England Biolabs, Beverly, MA) or 25ng (1µL) of pQe30 (Addgene). Note: 1µL of 
the DNA mixture was saved and diluted in 500µL of water to be used as a ‘time 
0’ sample for SSPE-qPCR (see section below). Samples were then transferred to 
a chilled, 1mm gap cuvette (Fisher Scientific, Waltham, MA) and electroporated 
using a ECM 630 Electro Cell Manipulator (BTX, Molliston, MA) at a field strength 
of 1000V/cm, resistance of 400Ω, and 25µF capacitance. Following 
electroporation, cuvettes were rinsed with 100µL of 1X IB buffer + 10% glycerol 
(40mM Tris-HCl pH 7.4, 25mM NaCl, 5mM MgCl2, and 10% glycerol). An 
additional 900µL of 1X IB buffer + 10% glycerol was then added, mixed, and 
spun in a table-top microcentrifuge at 21130 X G for 10 minutes at 4°C. The 
supernatant was then discarded and the pellet washed three times with 200µL of 
1X IB buffer + 10% glycerol and spun at the same conditions described above. 
After the washes, the final pellet was reususpended in 50µL of a solution 
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containing 40mM Tris-HCl pH 7.4, 25mM NaCl, 5mM MgCl2, 10% glycerol, 1mM 
pyruvate, 1mM ATP (Teknova), 1 mg/mL BSA (New England Biolabs), and 10µM 
dNTPs (Thermo Scientific) and incubated in a 37°C water bath for 1, 2, or 4 
hours. Following incubation, samples were pelleted in a table-top microcentrifuge 
at 21130 X G for 10 minutes at 4°C. The supernatant was discarded and the 
pellet washed twice with 200µL of 1X IB buffer + 10% glycerol and spun at the 
same conditions described above216.  
 
To assess their integrity, mitochondria were resuspended in 200µL DNase buffer 
containing 66 units DNase (New England Biolabs), 10% glycerol, 10mM Tris-HCl 
pH 8, and 1mM MgCl2 and incubated in a 37°C water bath for 30 minutes. 
Following incubation, samples were pelleted in a table-top microcentrifuge at 
21130 X G for 10 minutes at 4°C. The supernatant was discarded and the pellet 
washed twice with 200µL of a washing buffer containing 10% glycerol, 10mM 
Tris-HCl pH 7.4, and 1mM EDTA and spun at the same conditions described 
above216. Experiments conducted with or without DNase showed no difference in 
repair of plasmids containing an 8-oxo-guanine modification (19% vs 20% 
repair). Thus, confirming that following electroporation, mitochondrial membranes 
were not “leaky” and any DNA that did not enter the mitochondria was eliminated 




For all other experiments not utilizing DNase, mitochondria were resuspended in 
300µL lysis buffer (0.5% SDS, 10mM Trish-HCl pH 7.4, 150mM NaCl, 1mM 
EDTA, and 100µg proteinase K (New England Biolabs)) and incubated in a 37°C 
water bath for 15 minutes. Samples were then mixed with 300µL of a 50:50 
phenol:chloroform mixture. To create the 50:50 phenol:chloroform mixture, equal 
volumes of buffer-saturated phenol (Invitrogen) and chloroform (Acros) were 
mixed and spun in a table-top centrifuge at 1000 X G for 5 minutes at room 
temperature. The bottom layer of the mixture was then added to the sample, 
mixed, and spun in a table-top microcentrifuge at 21130 X G for 5 minutes at 
room temperature. The top layer was then transferred to a new microcentrifuge 
tube and ethanol precipitated using 18µL of 5M ammonium acetate (final 
concentration 0.3M), 12µL glycogen (Invitrogen, 60µg), 700µL of 100% ethanol, 
and precipitated at -20°C overnight216. 
 
Quantification of mitochondrial DPC repair. Precipitated samples were pelleted in 
a table-top microcentrifuge at 21130 X G for 10 minutes at 4°C, allowed to dry, 
and resuspended in 30µL of water. For experiments assessing the repair of the 
8-oxo-guanine lesion, 15µL of sample was mixed with OGG1 (2pmol) in a buffer 
containing 100mM NaCl, 1mM MgCl2, 20mM Tris-HCl pH 7.0, and water to reach 
a final volume of 30µL and incubated in a 37°C water bath for 30 minutes. One 
microliter of resuspended or OGG1-treated samples as well as ‘time 0’ samples 
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were then used to quantify repair using SSPE-qPCR (see Chesner and 
Campbell, DNA Repair, 2018 for details). 
 
KCl/SDS precipitation of recovered DNA from mitochondria. Following 
resuspension of recovered DNA from mitochondria, water was added to reach a 
final volume of 40µL and then divided in two. One microliter of 10% SDS (final 
concentration 0.5%) was then added to one tube and omitted from the other and 
incubated at 65°C for 10 minutes in a heating block. Two microliters of 1M KCl 
(100mM final concentration) was then added to the sample containing SDS and 
omitted from the other. These samples were incubated on ice for 5 minutes and 
then spun in a table-top microcentrifuge at 21130 X G for 10 minutes at 4°C to 
precipitate any protein-bound DNA66. The supernatant (containing DNA not 
bound to protein) was then run on a 1% agarose gel at 60V for 2 hours, stained 
with ethidium bromide (0.5µg/mL) for 30 minutes, and destained in water for 30 
minutes. Gels were imaged for 0.3 seconds on a Thermo Scientific myECL 
Imager and DNA bands quantified using ImageJ. ImageJ creates density 
histograms of each DNA band in order quantitate the amount of DNA present. 
Values generated by the program (arbitrary units) are then subtracted to obtain 
differences in intensity between samples treated with and without KCl/SDS 
(Figure 4.7). These differences were averaged from three different experiments 
in which DPC-containing plasmids were electroporated with a homologous or 
non-homologous donor and analyzed using a student t-test to assess 
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significance. Using this method, a greater difference in intensity between 
samples treated with and without KCl/SDS is associated with lower DPC repair. 
This is because unrepaired samples still crosslinked to protein will be precipitated 
by the KCl/SDS treatment resulting in a greater loss of DNA from the supernatant 
compared to repaired DNA (no longer containing a DPC) which will remain in 
solution. 
 
KCl/SDS precipitation of mitochondrial DNA treated with cisplatin. Twenty 15cm 
dishes of HT1080 cells were grown to confluency. Five mL of a 5mM cisplatin 
stock was mixed with serum-free media in a total volume of 250mL. Growth 
media was then removed and replaced with 25mL of serum-free media with or 
without drug and incubated at 37°C for 3 hours. Following incubation, cells were 
washed with 5mL of 1X PBS, scrapped into conical tubes, and spun in a table-
top centrifuge at 1000 X G for 5 minutes at room temperature. Cell pellets were 
then resuspended in 4mL isolation buffer (0.3M mannitol, 0.1% BSA, 0.2mM 
EDTA, and 10mM HEPES adjusted to a final pH of 7.4) and lysed in a glass 
dounce homogenizer (357542, Wheaton) for 5 strokes with the loose pestle and 
5 strokes with the tight pestle. Samples were then divided into 1.5mL 
microcentrifuge tubes and spun at 1000 X G in a table-top microcentrifuge for 10 
minutes at 4°C. The supernatant was transferred to a new tube and spun in a 
table-top microcentrifuge at 14000 x G for 15 minutes at 4°C to pellet the 
mitochondria217. Mitochondrial DNA was purified using alkaline lysis with SDS 
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and resuspended in 40µL TE (pH 8.0) containing 20µg/mL RNase A203. Each 
sample was then divided in half and subjected to KCl/SDS precipitation and 
quantification as described above.  
 
Cloning of a 475bp human mitochondrial insert into M13mp18. A portion of the 
human mitochondrial genome was cloned into the plasmid backbone of pUCIDT-
AMP (University of Minnesota’s Genomic Center) and digested with Kpn1 and 
Sac1 for 2 hours in a 37°C water bath to excise a 475bp fragment. In parallel, a 
modified M13mp18 plasmid containing a kanamycin resistance gene (see 
Chesner and Campbell, DNA Repair, 2018 for details) was linearized using the 
same conditions and run on a 0.8% low-melt agarose gel. Digestion products 
were excised with a razor blade and ligated at a 1:5 vector to insert ratio 
overnight at 16°C. The next day, 1µL of the ligation mixture was transformed into 
NEB Turbo electrocompetent bacteria (New England Biolabs) and plated on LB 
agar plates with kanamycin (50µg/mL). Individual clones containing the 
mitochondrial insert were screened by restriction digest of double-stranded DNA. 
Single-stranded virion DNA was subsequently purified, primer extended with an 
8-oxo-guanine-containing oligonucleotide (Table 4.1), and crosslinked as 
described in Chesner and Campbell, DNA Repair, 2018. Crosslinked plasmids 
containing the human mitochondrial insert (M13-Kan-Mito) were electroporated 
into purified mitochondria from the HEK293T cells, as described above, without a 




DPC-containing plasmids are repaired by the NER pathway. 
One of the advantages of the SSPE-qPCR assay is its ability to assess the repair 
of a variety of lesions on plasmid DNA. We first assessed the repair of DPC-
containing plasmids using SSPE-qPCR by trapping the repair protein human 
oxoguanine glycosylase (OGG1) to the deoxyribose backbone and saw 
significantly decreased repair in NER-deficient cells (27% vs 3%, Table 3.2). We 
next wanted to test the hypothesis that lesions attached to the DNA base are 
also repaired by the NER pathway. To do this, the OGG1 protein was crosslinked 
to a guanine or cytosine base on an oligonucleotide complementary to M13mp18 
(see Methods for details). This DPC-containing oligonucleotide was then 
phosphorylated, annealed, extended, and purified as previously described91. 
Following transfection into wild-type (V79) and NER-deficient (V-H1) Chinese 
hamster fibroblasts, DPC-containing plasmids attached to the guanine base were 
34% repaired by 8 hours in V79 cells compared to 10% in V-H1 cells. 
Interestingly, DPCs attached to cytosine were not as efficiently repaired in neither 
V79 cells (10%) nor V-H1 cells (5%), suggesting that chemical linkage can 
influence repair of DPCs (Figure 4.1).  
Previously, we reported that smaller DNA-peptide crosslinks were repaired 
more efficiently than larger DNA-protein crosslinks in wild-type cells and that their 
repair was also dependent on the NER pathway91. To assess repair of DNA-
peptide crosslinks attached to a nucleotide base, an 11mer peptide synthesized 
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from the substance P protein was crosslinked to the N7 position of guanine on an 
oligonucleotide and extended onto single-stranded DNA as described above. 
These DNA-peptide crosslinks were 57% repaired by 8 hours in V79 cells and 
26% repaired in V-H1 cells after 8 hours (Figure 4.1). These results confirm the 
hypothesis that plasmids containing smaller DNA-peptide crosslinks attached to 
the nucleotide base are also more efficiently repaired in wild-type cells and are 
substrates for repair via the NER pathway. Interestingly, background levels of 
DPC repair in NER-deficient cells were much higher compared to DPCs attached 
to the deoxyribose backbone. Therefore, we hypothesize that another DNA repair 
pathway may be able to repair lesions attached to the DNA base that is not able 
to remove DPCs attached to the backbone.  
 
The protease Spartan (and not the proteasome) is involved in repair of 
DPC-containing plasmids. 
Previous investigators have provided evidence for the role of the protease 
Spartan in DPC repair6,96,176. However, there is conflicting data regarding the 
involvement of the proteasome in the degradation of larger DPCs prior to 
repair87,92. To investigate the role of the proteasome in the repair of DPC-
containing plasmids using the SSPE-qPCR assay, wild-type Chinese hamster 
(V79) cells were pretreated with the proteasome inhibitor lactacystin (10µM) for 3 
hours prior to transfection with damaged substrates. After 8 hours, plasmids 
containing an 8-oxo-guanine lesion showed negligible repair (1% higher) in drug 
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treated cells compared to untreated. Repair of a cholesterol lesion was 
significantly reduced in drug-treated cells (35% decrease) while DPC repair was 
slightly higher in cells treated with the inhibitor compared to untreated (19% 
increase, Figure 4.2). Previous investigators have shown that cholesterol lesions 
are repaired by the NER pathway in mammalian cells91,182. Therefore, we were 
not surprised to see that proteasome inhibition interfered with the NER repair of 
the cholesterol lesion46,218,219. Additionally, our results showed no decrease in 
repair of DPC-containing plasmids in the presence of a proteasome inhibitor. 
Suggesting that another protease (besides the proteasome) is involved in the 
repair of this particular lesion.  
Xenopus egg extracts have commonly been used to study the role of the 
protease Spartan in DPC repair94. However, Spartan knockouts are 
embryonically lethal208. Therefore, we used mouse embryonic fibroblasts 
hemizygous for the Spartan gene to assess its role in the repair of DPC-
containing plasmids using SSPE-qPCR220. Results from these experiments 
showed 50% repair of DPC-containing plasmids in both wild-type (MEF) and 
mutated (MEF7) cells after 3 hours. However, DPC repair in mutants were 
decreased (59%) compared to wild-type (93%) 8 hours post-transfection (Figure 
4.2). These results support the hypothesis that hemizygous clones are not able 
to repair DPC-containing plasmids as efficiently as wild-type cells due to 
decreased levels of Spartan production, illustrating Spartan’s role in DPC repair. 
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DPCs are repaired via homologous recombination in the nucleus of NER-
deficient mammalian cells. 
Previous experiments performed in bacteria have shown that clones deficient in 
the NER and HR pathways are hypersensitive to DPC-inducing agents61. 
However, hypersensitivity assays performed in yeast, only indicated a role for the 
NER pathway while the involvement of the HR pathway in mammalian cells 
remains unclear60. To assess the role of HR in DPC repair using SSPE-qPCR, 
OGG1-containing plasmids attached to an abasic site were transfected into 
mammalian cells in the presence of a homologous donor (undamaged M13mp18 
plasmid) or a non-homologous donor (pQe30 plasmid). In NER-deficient hamster 
(V-H1) and human (XPD) cells, DPCs cotransfected with a homologous donor 
showed significantly increased repair (22% and 73%, respectively) compared to 
lesions cotransfected with a nonhomologous donor (11% and 14%, respectively). 
Interestingly, wild-type (V79) cells showed no difference in DPC repair with or 
without a homologous donor (Figure 4.3). These results support the hypothesis 
that homologous recombination of DPC-containing plasmids only occurs in the 
absence of the NER pathway.  
 
Nuclear homologous recombination of DPC-containing plasmids is 
dependent on the RAD51 protein. 
During homologous recombination, 5’ ends of DNA are chewed back by 
nucleases to create 3’ overhangs of single-stranded DNA. This single-stranded 
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DNA is initially coated by the RPA (DNA replication protein A) protein and 
activates the ATR response (Ataxia Telangiectasia and Rad3-related protein). A 
RAD51 nucleofilament is then assembled and replaces the RPA coat to begin its 
search for homology211. To confirm the involvement of the HR pathway in the 
repair of DPC-containing plasmids, NER-deficient human cells (XPD) were 
pretreated with a RAD51 inhibitor (B02) prior to transfection213. We hypothesized 
that inhibition of the RAD51 protein would block HR repair and show no increase 
in repair in the presence of a homologous donor. OGG1-linked plasmids showed 
significantly decreased repair in B02-treated cells (15%) compared to non-drug 
treated cells (59%) after 3 hours (Figure 4.4). However, DNA-peptide crosslinks 
formed by degrading OGG1-crosslinks with trypsin (see Chesner and Campbell, 
DNA Repair, 2018 for details) showed no difference in repair between drug-
treated and non-treated cells. This result is consistent with previous observations 
from Ide et al. that HR is only involved in the repair of larger DNA-protein 
crosslinks92. However, it is still unclear which repair pathway is responsible for 
the background levels of repair that occur in the absence of both the NER and 
HR pathways. Lead candidates include other double-strand break repair 
pathways such as non-homologous end-joining (NHEJ) and micro-mediated end-





Homologous recombination of DPC-containing plasmids is not dependent 
on the RAD51D protein in the nucleus. 
There are multiple paralogs of the RAD51 protein expressed in invertebrates 
including RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3221. To further 
characterize the involvement of these paralogs in homologous recombination of 
DPC-containing plasmids, we performed experiments in Chinese hamster 
ovarian cells deficient in the RAD51D gene210. We hypothesized, that cells 
deficient in the RAD51D gene would not show increased repair of DPC-
containing plasmids in the presence of a homologous donor. However, both wild-
type (19% vs 33%) and mutated cells (27% vs 47%) showed increased DPC 
repair in the presence of a homologous donor (Figure 4.5). Together with the 
data presented above, these results support the interpretation that the RAD51 
gene but not the RAD51D paralog is essential for homologous recombination of 
DPC-containing plasmids in the nucleus of mammalian cells.  
 
Repair of DPC-containing plasmids in purified nuclei.  
The reagent lipofectamine used in the experiments above is a cationic agent 
which relies on endocytosis to take up plasmid DNA and deliver it to the 
nucleus222. Since proteolysis is hypothesized to be involved in repair of larger 
protein crosslinks, we wanted to rule out the possibility that proteolytic or 
nucleolytic processing during endocytosis could influence DPC repair results. 
Purified nuclei from wild-type hamster cells (V79) were electroporated with 
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plasmids containing an 8-oxo-guanine or DPC lesion and repair quantified using 
SSPE-qPCR. Results from these experiments showed 29% repair of 8-oxo-
guanine lesions and 31% repair of DPCs (Figure 4.6). As shown, in Figure 4.3, 
DPC-containing lesions were ~30% repaired in V79 cells 8 hours post-
transfection. These results confirm that repair of DPC-containing plasmids occurs 
to a similar extent when electroporated directly into purified nuclei or transfected 
into intact mammalian cells. Thus, any alterations to the damaged substrate 
during endocytosis are most likely not a factor in repair.  
Above we have presented evidence for the NER and HR pathway in the 
repair of DPC-containing plasmids in mammalian cells using the SSPE-qPCR 
assay. However, the mitochondrial genome is also exposed to DPC-inducing 
agents such as chemotherapeutics and ionizing radiation223,224. Surprisingly, little  
work as has been done to study repair of these lesions in the mitochondria225. 
Since it has been shown that the NER pathway is not present in the 
mitochondria, we hypothesized that DPCs would be repaired via homologous 
recombination and that we could quantify the repair using the SSPE-qPCR 
assay127. First, we confirmed that DPCs form on mitochondrial DNA following 






Treatment of human cells with cisplatin results in higher formation of 
DPCs. 
Human HT1080 cells were treated with or without 100µM cisplatin for 3 hours 
and mitochondrial DNA purified as described above. KCl/SDS precipitation is a 
common assay that has been used to quantify DPCs following exposure to a 
DPC-forming agent66. The SDS binds to the protein and, following the addition of 
KCl, is precipitated out of solution, pulling down any DNA crosslinked to protein. 
The DNA is then run on a gel and quantified using scanning densitometry to 
calculate differences between DNA treated or not treated with KCl/SDS. DNA 
containing a higher number of protein crosslinks will show a larger difference 
between KCl/SDS treated and nontreated samples. Results from these 
experiments showed that cells treated with cisplatin showed a significantly larger 
difference between samples treated or not treated with KCl/SDS than cells not 
treated with drug. These results support the conclusion that cisplatin-induced 
DPCs significantly accumulate in mitochondrial DNA (Figure 4.7).  
 
DPC-containing plasmids are repaired via homologous recombination in 
mitochondria. 
To test the hypothesis that DPCs are repaired via homologous recombination in 
mitochondria, we electroporated DPC-containing plasmids with a non-
homologous (qQe30) or homologous donor (M13) into mitochondria purified from 
wild-type hamster (V79) and human (HEK293T) cells. The mitochondria were 
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then incubated for 2 hours in a 37°C water bath in the presence of pyruvate, 
ATP, BSA, and dNTPs for 2 hours, lysed, and repair quantified using SSPE-
qPCR. Since it has been shown that mitochondria lack the NER machinery, we 
predicted that damaged substrates electroporated with pQe30 would not be 
repaired, while those electroporated with M13 would be repaired via homologous 
recombination. As predicted, neither hamster nor human cells repaired DPC-
containing plasmids electroporated with pQe30. However, substrates 
electroporated with M13 were 11% repaired in hamster cells and 9% repaired in 
human mitochondria after 2 hours (Figure 4.8). To assess the repair kinetics of 
these plasmids, we performed a time course in which mitochondria recovered for 
1, 2, or 4 hours prior to quantification via SSPE-qPCR. These results indicated 
that repair occurred at a near-linear rate over time. Finally, as another 
confirmation of DPC repair, plasmid DNA recovered from mitochondria was 
treated with or without KCl/SDS and run on a gel to quantify DNA using scanning 
densitometry. Plasmid DNA co-electroporated with pQe30 showed a significant 
difference in DNA intensity between samples treated with or without KCl/SDS 
whereas samples co-electroporated with M13 showed no significant difference in 
DNA intensity (Figure 4.8). These results support the conclusion that DPC-
containing plasmids co-electroporated with M13 were not precipitated out of 
solution because they were repaired via homologous recombination. Overall, 
these results provide strong evidence for the repair of DPC-containing plasmids 
via homologous recombination in mammalian mitochondria. 
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Double-strand break-mediated homologous recombination of DPCs in the 
mitochondria is dependent on the RAD51 (but not the RAD51D) gene. 
It is known that meiotic homologous recombination is proceeded by the formation 
of a double-strand break58. Assays examining interchromosomal and 
intrachromosomal homologous recombination as well as HR on plasmids has 
been shown to be stimulated by a double-strand break226-228. Initiation of 
homologous recombination has also been shown by targeting double-strand 
breaks to specific loci using the restriction endonuclease I-Sce1229,230. Therefore, 
we hypothesized that creation of a double-strand break at the crosslinking site of 
the DPC would increase repair. To test this hypothesis, DPCs crosslinked to the 
EcoRI recognition site of the plasmid (Table 4.1) were digested with the 
restriction enzyme EcoRI prior to co-electroporation into mitochondria with a 
homologous donor. As predicted, the presence of a double-strand break 
facilitated DPC repair, showing a twofold increase in repair after 2 hours (22% in 
hamster cells and 16% in human cells, Figure 4.9). 
One of the key steps in homologous recombination is the synthesis of a 
new DNA strand, requiring the use of deoxynucleotide triphosphates (dNTPs)231. 
To test whether the absence of dNTPs would inhibit mitochondrial DPC repair, 
we incubated electroporated mitochondria without dNTPs. Even when co-
electroporated with a homologous donor, DPC-containing plasmids were not able 
to be repaired in the absence of dNTPs. Thus confirming that DNA synthesis is 
an essential process in repairing these damaged substrates.  
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To test another step in the homologous recombination pathway, we pre-
treated human cells with the RAD51 inhibitor B02 prior to mitochondria 
purification. RAD51 is a key gene that facilitates the search and invasion of a 
homologous donor during repair210. We predicted that without this gene, HR 
repair of the DPC-containing plasmids would not occur. Interestingly, cells 
treated with the RAD51 inhibitor showed no DPC repair while Chinese hamster 
cells deficient in the RAD51D gene were able to repair the damage (Figure 4.9). 
These results demonstrate that the RAD51 (but not the RAD51D paralog) gene is 
essential in HR repair of DPC-containing plasmids in the mitochondria.  
 
The mitochondrial genome can be used as a donor to repair DPC-
containing plasmids. 
As shown above, DPC-containing plasmids are only repaired in mitochondria 
when co-electroporated with a homologous donor plasmid. Therefore, we wanted 
to test the hypothesis that the mitochondrial genome could be used as a 
homologous donor for DPC repair. To do this, a 475bp sequence from the human 
mitochondrial genome was cloned into a plasmid and crosslinked with the OGG1 
protein. This plasmid was then electroporated into human mitochondria and 
repair quantified after 2 hours using SSPE-qPCR. To ensure that the primers 
used for the SSPE-qPCR do not amplify the mitochondrial genome, one primer 
was complementary to the mitochondria insert (forward, Table 4.1) while the 
other (reverse, Table 4.1) was complementary to the M13 portion of the plasmid. 
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Results from these experiments showed 17% repair of DPC-containing plasmids 
after 2 hours (Figure 4.10). Thus, confirming the hypothesis that the 




Data presented above confirms and extends observations that both nucleotide 
excision repair and homologous recombination play a role in DPC repair. First, 
we have extended our previous work and shown that NER is capable of repairing 
proteins and peptides crosslinked to plasmid DNA via a variety of chemical 
crosslinks. Our past work showed a significant decrease in the repair of the 
OGG1 protein crosslinked to an abasic site in NER-deficient cells. However, 
proteins can be attached to DNA via multiple linkages89. Therefore, we 
synthesized three oligonucleotides containing OGG1 crosslinked to the N7 
position of guanine or the 5formyl position of cytosine as well as an 11mer 
peptide crosslinked to the N7 position of guanine to directly compare differences 
in repair. Results from these experiments confirmed that both types of crosslinks 
were substrates for the NER pathway and that DNA-peptide crosslinks were 
repaired more efficiently than larger DNA-protein crosslinks in wild-type cells. 
Interestingly, repair of these adducts in NER-deficient hamster cells was higher 
than previously seen using crosslinks attached to an abasic site on DNA. These 
results could indicate that proteins attached to the nucleotide base may be 
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substrates for other repair pathways such as non-homologous end-joining and 
micro-mediated end-joining. Additionally, repair of OGG1 crosslinked to 5formyl 
cytosine was significantly decreased in wild-type hamster cells compared to 
lesions attached to the N7 guanine position. Thus suggesting that some lesions 
are repaired more efficiently than others and that the nature of the chemical 
crosslink influences DPC repair.  
Second, we utilized SSPE-qPCR to examine the role of HR in nuclear 
DPC repair. Other investigators have used hypersensitivity assays with mutants 
from bacteria, yeast, and mammalian cells to show a role for homologous 
recombination in the repair of DNA-protein crosslinks61,62,232. However, DPC-
forming agents such as formaldehyde induce other types of damage besides 
DPCs233. Studies performed in E. coli have proposed a size limit for repair of 
DPCs by the NER pathway and suggested that DPCs larger than 10 kDa are 
repaired via HR2,92. Other models using Xenopus egg extracts have proposed 
that larger DNA-protein crosslinks are proteolyzed into smaller adducts and then 
bypassed by the replication machinery during translesion synthesis101. To gain a 
better understanding of the role of homologous recombination in mammalian 
cells, we co-transfected OGG1-linked plasmids with a homologous donor into 
NER-deficient hamster and human cells and studied their repair using SSPE-
qPCR. One advantage of using this assay to study HR, is that intermediates such 
as proteolyzed DNA-peptide crosslinks or double-strand breaks will block the Taq 
polymerase during strand extension, ensuring that proteolysis or translesion 
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synthesis are not quantified as repair events. Results from these experiments 
showed significantly increased repair of DPCs via HR in NER-deficient cells. We 
also predicted that providing a homologous donor for repair of these DPC-
containing plasmids in wild-type cells would increase repair. Interestingly, wild-
type cells co-transfected with a damaged substrate and donor plasmid did not 
show an increase in DPC repair. These results suggest that normal cells rely on 
the NER pathway as a primary mechanism to repair these lesions and that HR 
only occurs in the absence of the NER pathway. It would be interesting to 
investigate, in future experiments, how DPCs are repaired in cells deficient in 
both the NER and HR pathways. 
Third, we confirmed the role of nuclear HR in repair of DPC-containing 
plasmids by pre-treating NER-deficient cells with a RAD51 inhibitor prior to 
transfection. We predicted that inhibition an essential HR protein would prevent 
DPC repair. Results from these experiments showed that repair of DPC-
containing plasmids was significantly decreased in cells treated with the RAD51 
inhibitor. Next, we examined nuclear DPC-repair in the absence of a RAD51 
paralog. RAD51 paralogs form 2 distinct complexes: RAD51B-RAD51C-
RAD51D-XRCC2 (BCDX2) and RAD51C-XRCC3 (CX3)234. SiRNA studies of the 
RAD51 paralogs have indicated a role for the BCDX2 complex in the recruitment 
of RAD51 to Isce1-induced double-strand breaks235. Therefore, we predicted 
hamster cells deficient in the RAD51D paralog would inhibit the recruitment of 
RAD51 and prevent DPC repair via HR. However, RAD51D KO cells showed no 
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difference in the repair of DPC-containing plasmids compared to wild-type in the 
presence of a homologous donor. It is known that HR can also occur via a 
RAD52-mediated pathway236. Therefore, future studies will examine the role of 
other RAD51 paralogs as well as inhibition of the RAD52 protein in the repair of 
DPC-containing plasmids. Another interesting observation from these studies 
was that pretreatment of cells with a RAD51 inhibitor showed no difference in 
repair of DNA-peptide crosslinks compared to untreated. Although these results 
are consistent with previous observations that HR is involved in the repair of 
DPCs larger than 10 kDa, it is unclear how these DNA-peptide crosslinks are 
repaired in the absence of NER92. Future studies will examine other double-
strand break repair pathways such as non-homologous end-joining (NHEJ) by 
pre-treating cells with a protein kinase inhibitor prior to transfection.  
The data presented above convincingly demonstrates nuclear repair of 
DPC-containing plasmids via HR in the absence of the NER pathway. Since 
mitochondria have been shown to lack the NER pathway, it seemed obvious to 
hypothesize that repair of these lesions in mitochondria would also involve the 
HR pathway. Finally, we used SSPE-qPCR to investigate the role of HR in repair 
of DPC-containing plasmids electroporated into purified mitochondria. 
 DPC formation is known to occur in mitochondria following exposure to 
crosslinking agents such as formaldehyde and oxidative processes237. However, 
until now, no mechanism has been proposed for their repair. In fact, Borisov et al. 
saw no decrease in mitochondrial DPC accumulation over time in the brain and 
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spleen of rats following exposure to radiation and suggested that mitochondria 
are not capable of repairing DPCs238. However, results from the experiments 
above indicate that DPC-containing plasmids electroporated into mitochondria 
are repaired in the presence of a homologous donor plasmid or a homologous 
portion of the mitochondrial genome. Further characterization of HR repair in the 
mitochondria was reflective of results obtained in the nucleus. Homologous 
recombination of DPC-containing plasmids was prevented in the presence of a 
RAD51 inhibitor but was still able to occur in the mitochondria of RAD51D-
deficient cells.  
As discussed above, homologous recombination is stimulated by the 
formation of double-strand breaks239. Therefore, we hypothesized that DPCs 
created at the site of a double-strand break, would show higher amounts of 
repair. As predicted, plasmids cut with a restriction enzyme at the crosslinking 
site showed increased HR repair. Finally, we confirmed that HR repair of DPC-
containing plasmids involved strand synthesis by incubating electroporated 
mitochondria in the absence of dNTPs. Results from these experiments showed 
that DPC repair was not able to occur without dNTPs, indicating that DNA 
synthesis is required for HR repair of these plasmids.  
Other models of DPC repair such as proteolysis have yet to be 
investigated in the mitochondria. It would also be interesting to assess the repair 
efficiency of other types of crosslinks (i.e. proteins crosslinked to the nucleotide 
base) to gain a greater understanding of DPC repair mechanisms in the 
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mitochondria. Insight into these pathways can ultimately provide new avenues for 
cancer treatments. For example, work done by Shauna Kelly’s group has shown 
that targeting the topoisomerase II inhibitor doxorubicin to mitochondria is toxic to 
drug-resistant cancer cells,240 indicating a role for mitochondria-targeting DPC-
forming drugs in the treatment of cancer158,241,242.  
Overall, the work above details initial observations of DPC repair via HR. 
However, this system can be further exploited to gain a greater understanding of 
HR repair mechanisms in the mitochondria and the repair of other lesions such 
as double-strand breaks. Thus far, indirect evidence has been given for the 
NHEJ and HR double-strand break repair pathways in mitochondria 138,243. 
Further work using the method described above could provide a more detailed 
mechanism of these processes in mitochondria. For example, capture 
experiments of biotin-labeled oligonucleotides could be used to pull-down repair 
intermediates and identify repair proteins recruited to the lesion. Taken together, 
this work is the first to provide convincing evidence for homologous 
recombinational repair of DPC-containing plasmids in the nucleus and 









Figure 4.1: Decreased repair of DPC-containing plasmids in NER-deficient 
hamster cells. Plasmids containing the OGG1 protein crosslinked to a 7-deaza-
guanine residue (A), 11-mer peptide crosslinked to a 7-deaza-guanine residue 
(B) or OGG1 protein crosslinked to a 5-formyl-cytosine residue were transfected 
into wild-type Chinese hamster lung fibroblasts (V79) or isogenic NER-deficient 
cells (V-H1). Cells recovered for 8 hours, were lysed, and repair quantified using 






Figure 4.2: DPC repair is dependent on the protease Spartan and not the 
proteasome. A: Wild-type Chinese hamster (V79) cells were or were not 
incubated in the presence of the proteasome inhibitor lactacystin (10µM) for 3 
hours prior to the transfection of damaged substrates. Values given indicate the 
difference in percent repair (calculated using SSPE-qPCR) between cells treated 
or not treated with drug. B: Wild-type mouse embryonic fibroblasts (MEF) and 
hemizygous clones (MEF7) deficient in the protease Spartan were transfected 
with DPC-containing plasmids and repair calculated using SSPE-qPCR at 3 and 





Figure 4.3: Increased repair of DPC-containing plasmids crosslinked to the 
deoxyribose in NER-deficient cells with a homologous donor. OGG1-
containing plasmids were co-transfected with either a homologous (+ donor) or 
non-homologous donor (- donor) into hamster (V79 and V-H1) or human (XPD) 
cells. Cells recovered for 8 hours, were lysed, and repair quantified using SSPE-







Figure 4.4: Decreased homologous recombination of DNA-protein 
crosslinks but not DNA-peptide crosslinks in the presence of a RAD51 
inhibitor. NER-deficient human fibroblasts (XPD) were incubated with or without 
the RAD51 inhibitor B02 (5µM) for 1 hour prior to transfection with plasmids 
crosslinked to hOGG1 or trypsin-digested hOGG1 with or without a homologous 
donor. Cells recovered for 3 hours, were lysed, and repair quantified using 
SSPE-qPCR (see methods for details).  Percent HR repair was calculated by 
subtracting repair in the presence of a homologous donor from repair in the 






Figure 4.5: Homologous recombination of DPC-containing plasmids is not 
dependent on RAD51D. Plasmids crosslinked to hOGG1 to the deoxyribose 
were co-transfected with either a homologous (W/ donor) or non-homologous 
donor (W/o donor) into Chinese hamster ovarian AA8 cells deficient in the 
RAD51D gene (51D1) and isogenic corrected cells (Corr). Cells recovered for 8 
hours, were lysed, and repair quantified using SSPE-qPCR (see methods for 







Figure 4.6: Repair of damaged plasmids in purified nuclei. Plasmids 
containing either an 8-oxo-guanine modification or OGG1 crosslink were 
electroporated into purified nuclei from wild-type hamster cells, incubated at 37°C 
for 2 hours, and repair quantified using SSPE-qPCR. Values depict mean 







Figure 4.7: Formation of cisplatin-induced DNA-protein crosslinks in 
human cells. Human HT1080 cells were treated with 100µM cisplatin and 
mitochondrial DNA purified as described in methods. A: Purified DNA was then 
treated (+) or not treated (-) with KCl/SDS and run on a gel. B: Density of gel 
bands were quantified using ImageJ and difference in arbitrary units (AU) 
calculated. C: Average difference in density calculated from three experiments. 










































































































































































































































































































Figure 4.9: Mitochondrial repair of DPCs in dependent on dNTPs and the 
RAD51 protein. A: (-dNTPs) refers to DPC-containing plasmids were 
electroporated into human HEK293T mitochondria with an undamaged, 
homologous donor and allowed to recover for two hours in the absence of 
deoxynucleotide triphosphates. (-RAD51) refers to HEK293T cells were 
pretreated with the RAD51 inhibitor B02 (5µM) for one hour prior to mitochondrial 
purification. RAD51D KO refers to Chinese hamster ovarian cells that are 
deficient in the RAD51D gene. B: DPC-containing plasmids were digested with 
(+digest) or without (-digest) the restriction enzyme EcoRI adjacent to the 
crosslinking site and electroporated in wild-type (V79) cells. All DPC-containing 
plasmids were electroporated with a homologous donor, incubated for 2 hours, 





Figure 4.10: Repair of DPC-containing plasmids using the mitochondrial 
genome as a homologous donor. A plasmid containing 475bp of homology 
(blue) with the mitochondrial genome was crosslinked with OGG1, electroporated 
in HEK293T cells, allowed to recover for 2 hours, and repair quantified with 
SSPE-qPCR using primers complementary to the mitochondrial insert (blue 
arrow) and to the M13 plasmid (green arrow). Values depict mean percent repair 





























DNA-damaging chemotherapeutics are used to treat a wide variety of cancers1. 
Unfortunately, cancers can develop resistance to these drugs244. It has been 
shown that increased expression of DNA repair proteins is correlated with drug 
resistance245. DNA-protein crosslinks (DPCs) are one of the toxic lesions formed 
by these chemotherapeutics. However, because DPCs are induced with other 
types of DNA damage, it is unclear what role DPC repair mechanisms play in 
chemotherapeutic resistance. The goal of this research was to gain insight into 
the pathways involved into DPC repair by studying the repair of synthetic DPCs 
crosslinked to plasmid DNA and transfected into mammalian cells.  
From this work, a new assay termed strand-specific primer extension-
quantitative polymerase chain reaction (SSPE-qPCR) was developed and used 
to quantify DPC-containing plasmids (as well as other lesions) transfected into 
mammalian cells of different genetic backgrounds and recovered over time. The 
important feature of this assay lies in the multiple rounds of primer extension that 
recovered plasmids are subjected to using Taq polymerase and a primer 
complementary to the originally damaged strand. Unrepaired adducts blocked 
extension of these primers and did not generate any additional DNA strands. 
However, repaired DNA was extended during this step and produced additional 
DNA strands. QPCR was then used to quantify how many additional strands of 
DNA were produced during primer extension and calculate what percent of 
recovered plasmids had been repaired. Another unique feature of the assay was 
that conditions such as protein size, sequence context, and nature of the 
	
141	
chemical crosslink could be altered to assess how these factors influenced 
repair. This assay was then exploited to investigate the role of nucleotide 
excision repair (NER), homologous recombination (HR), and proteolysis in the 
repair of DPCs in the nucleus. 
As mentioned above, DPCs are formed by endogenous and exogenous 
agents randomly throughout the genome. However, mitochondrial DNA is also 
susceptible to these DNA-damaging agents and the formation of DNA-protein 
crosslinks225. Because mitochondria are frequently exposed to oxidative damage, 
repair pathways such as base excision repair have been a main focus in 
mitochondrial DNA repair research246. To examine DPC repair in the 
mitochondria, the SSPE-qPCR assay was used to quantify the repair of DPC-
containing plasmids electroporated into purified mitochondria. Incubation of the 
damaged substrate in the presence of pyruvate, BSA, dNTPs, and ATP was 
sufficient to examine repair events over a time course of 4 hours. Results from 
these experiments showed a role for the homologous recombination pathway in 
DPC repair, providing the first evidence for DPC repair in this organelle. These 
experiments validate future use of this assay to gain a greater understanding of 
DPC and HR repair in mitochondria.  
Overall, this work has contributed to current literature aimed to better 
understand DNA repair mechanisms in order to advance chemotherapeutic 
treatment of cancer patients. Once understood, these pathways can then be 
exploited to increase the efficacy of DNA-damaging drugs. An example of this 
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therapeutic strategy is the combinational use of temazolamide and O6-
benzylguanine in treating drug-resistant glioma247. Temzazolamide is a 
chemotherapeutic which alkylates DNA and is used to treat malignant glioma. 
However, patients who are resistant to this drug have a poor prognosis for 
survival. O6-benzylguanine is a repair substrate for the enzyme O6-alkylguanine-
DNA alkyltransferase (AGT) and can irreversibly inactive AGT in order to 
increase the effectiveness of temozolomide248. In this case, understanding how 
alkylated DNA is repaired in cells, improved the therapeutic efficacy of 
temozolomide by using a combination therapy involving a DNA repair substrate. 
Considering the large number of chemotherapeutics which induce DNA-protein 
crosslinks, it is logical to predict that a similar strategy could be used in cancers 
resistant to DPC-inducing agents. Thus, understanding the repair mechanisms 
involved in DPC repair can be used to improve therapeutic strategies and 



































The work presented above has contributed to the field by providing a new 
assay to gain insight into the repair mechanisms of polymerase-blocking lesions 
on exogenous DNA in mammalian cells. Future work can utilize this assay to 
gain further insight into repair mechanisms of specific lesions in the nucleus and 
mitochondria. For example, it would be interesting to investigate the role of 
proteolysis in the repair of larger DNA-protein crosslinks (DPCs).  
Current studies suggest that proteins larger than 10 kDa are digested into 
smaller peptides prior to removal92. However, it is still unclear what protease is 
responsible for the degradation and how the enzyme is recruited to the damage. 
To address this question, a biotinylated, DPC-containing oligonucleotide could be 
electroporated into purified nuclei, recovered, and analyzed using mass 
spectrometry. Using this method, one could identify the sequence of the 
remaining DNA-peptide on the oligonucleotide and gain insight into the protease 
responsible by examining its recognition sequence. Polyubiquitination is a 
modification used to signal protein degradation by the proteasome249. To assess 
the role of ubiquitin in proteolysis signaling during DPC repair, substrates 
recovered from cells at early time points could be analyzed for ubiquitin via 
western blot250. Another strategy would be to treat plasmids containing larger 
DPCs with acetyl succinimide to modify lysine residues and prevent 
ubiquitination251. Decreased repair of these substrates would confirm a role for 
ubiquitin modification in their repair. Researchers have also shown the protease 
Spartan to be involved in the proteolysis of DPCs176. However, most studies have 
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been performed in extracts since knock-out cells are embryonically lethal100. To 
assess the role of Spartan in DPC repair in intact cells, a cell line could be 
created in which the expression of Spartan is controlled under an inducible 
promoter. Using this strategy, it could be determined how much Spartan is 
needed to see repair of DPC-containing plasmids. Alternatively, cells transfected 
with a plasmid that expressed flag-tagged Spartan and could be used to pull-
down DPC-containing plasmids via immunoprecipitation.  
Another future direction of this work would be to further investigate 
mitochondrial repair mechanisms. For example, although proteolysis is believed 
to play a role in nuclear DPC repair, it is unclear if the same proteases (or any) 
are involved in mitochondrial DPC repair. This could be examined by 
electroporating DPC-containing plasmids of multiple sizes in purified 
mitochondria to assess their repair rate. Faster repair of DNA-peptide crosslinks 
would support the existence of a rate-limiting proteolysis step during repair. 
SiRNA knockdown of different mitochondrial proteases could then be used to 
identify which protease influences repair of larger DPC-containing plasmids. 
Although we have provided evidence for the repair of DPCs via mitochondrial 
homologous recombination, future experiments could investigate the recruitment 
of this repair machinery to the damaged site. For example, following 
electroporation, DPC-containing oligonucleotides could be treated with 
formaldehyde to crosslink protein recruited to the site of damage252. These 
proteins can then be released upon heating, resolved on a protein gel, and cut 
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out of the gel for identification via mass spectrometry. This strategy could be 
used to gain insight into the homologous recombination of double-strand breaks 
as well as DNA-protein crosslinks in the mitochondria. Sequence analysis of the 
recovered substrates could also assess repair-induced mutagenesis.  
Although nucleotide excision repair (NER) and homologous recombination 
(HR) are thought to be the primary pathways involved in DPC repair, cancerous 
cells can have defects in repair proteins, resulting in dysfunctional pathways107. 
Therefore, it is important to understand what other mechanisms are able to repair 
DPCs in the absence of the NER and HR pathway. One candidate for this repair 
is the non-homologous end-joining pathway (NHEJ) which is known to repair 
double-strand breaks253. This could be investigated by pretreating NER-deficient 
cells with a NHEJ inhibitor (such as a protein kinase inhibitor) prior to transfection 
with a damaged plasmid in the absence of a homologous donor.  
Insight into the role of the mechanisms described above in DPC repair 
could one day be used clinically in the development of inhibitors to prevent DPC 
repair and increase the effectiveness of DPC-forming chemotherapeutics. 
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